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3Summary
A ventilated, perfused isolated rat lung is described, allowing 
simultaneous measurement of pulmonary inflation pressure (PIP), 
pulmonary perfusion pressure (PPP) and lung weight (LW). The 
model has been demonstrated to be stable for a period of 2hrs under 
normoxic conditions (20% O2 /  75% N2 / 5% C 02). Exposure of the 
lung to a systemic hypoxia (95% N2 / 5% C 0 2), both in a single pass 
and recirculating system, resulted in an increase in both PPP and LW. 
No significant change in PIP was seen.
The increases in PPP and LW could be blocked by the ETa receptor 
antagonist BQ123, the ETb receptor antagonist BQ788 and the mixed 
ETa/ETb receptor antagonist bosentan, indicating the involvement of 
both the ETa and the ETb receptor in the responses seen. 
Furthermore, the endothelin converting enzyme inhibitor 
phosphoramidon, and agents which disrupted the function of the 
cytoskeleton and prevented secretion (colchicine and phalloidin) and 
inhibited peptide synthesis (cycloheximide) also prevented the 
increases in PPP and LW induced by hypoxia.
Exposure to hypoxia in a recirculating system results in an elevation of 
perfusate ET-1 levels. However, tissue ET-1 levels do not alter 
significantly, indicating synthesis and release of ET-1 in response to 
hypoxia.
In addition to this, prepro ET-1 mRNA levels increase in whole lung 
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9HYPOXIA AND HYPOXIC PULMONARY VASOCONSTRICTION
Hypoxia is defined as “...a diminished amount of oxygen...”. Hypoxia 
has many effects on tissues, which vary depending upon their location. 
Hypoxia causes dilation in systemic arteries, but constriction of the 
pulmonary vasculature (for review see Wadsworth, 1994). This 
hypoxic pulmonary vasoconstriction (HPV) is an important 
physiological response to maintain the ventilation/perfusion ratio and 
facilitate optimal oxygen uptake by the pulmonary circulation 
(Fishman, 1976). As HPV is a powerful active control mechanism in 
the pulmonary circulation it has been an area of intense debate and 
investigation. The first description of a response to hypoxia was noted 
by Bradford and Dean (1899). Modern research into the phenomenon 
of HPV was instigated by von Euler and Liljestrand in 1946, when they 
demonstrated the hypoxic pressor response in a series of elegant 
experiments in the anaesthetised cat. The vasoconstriction seen in 
response to hypoxia was not new, but the paper excited considerable 
interest.
Despite more than four decades of investigation into HPV, the 
mechanisms responsible for the response are still to be defined. Early 
research showed that autonomic activity was not essential for the 
development of HPV, as the response persists in isolated lungs 
(Hauge, 1968; Fishman, 1976; Szidon and Flint, 1977) and in 
transplanted human lungs (Robin eta!., 1987). HPV is also unaffected
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by adrenoceptor blockade (Malik and Kidd, 1973), catecholamine 
depletion (Goldring et al., 1962), sympathectomy (Fishman, 1961) and 
depletion of neuropeptides (McCormack et al, 1993). It therefore 
seems that intrinsic mechanisms within the vessels of the lung are 
responsible for HPV.
Recent reports have indicated that there are two main components to 
HPV. There is a rapid transient constriction of about 5 min, which 
generally falls towards, but does not reach the baseline (phase 1, 
Jensen et a l, 1992), which is commonly seen in pre-contracted 
preparations, and a slower, more sustained, phase (phase 2) which is 
endothelial dependent in most species (Jin et a l, 1992, Ward and 
Robertson, 1995). The transient phase 1 hypoxic pulmonary 
vasoconstriction appears to be due to K+ channel blockade (Weir and 
Archer, 1995), but the mechanism(s) underlying the phase 2 response 
are not clear.
Two main hypotheses for the mechanism(s) responsible for the phase 
2 HPV have been proposed. The first is the mediator hypothesis, 
where endogenous constrictor substances are released, endogenous 
dilator substances are suppressed, or a combination of the two occur, 
to elicit the HPV response (see Figure 1.1). The second hypothesis is 
a direct action of hypoxia upon the pulmonary vascular smooth muscle 
to elicit contraction (Barnes and Liu, 1995).
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Several vasoactive substances have been nominated as candidates 
for the vasoconstrictor mediator in the lung, including catecholamines 
(Fishman, 1976); histamine (Hauge, 1968); angiotensin-ll (Berkov, 
1974); 5-hydroxytryptamine (Fishman, 1976); platelet activating factor 
(McCormack et al., 1989a); ATP (McCormack et al., 1989b) and 
prostaglandins (Weir et al., 1976). All of these have proved to be non- 
essential for HPV, although they may all play a modulatory role in HPV 
(Barnes and Liu, 1995). Endothelins have also been proposed as a 
mediator for chronic (phase 2) HPV, but their onset of action is too 
slow, and duration of action too long, for them to mediate the acute 
(phase 1) HPV seen in some preparations. Several dilator substances 
have been proposed to be involved in HPV, including bradykinin (Weir, 
1978), prostacyclin (PGb) and nitric-oxide (NO). Bradykinin has been 
discounted as a vasodilator mediator of HPV in the rat, as it has been 
demonstrated to cause vasoconstriction in the rat lung (Lai et al.,
1994). It is interesting to note that in preparations with raised tone 
bradykinin has been shown to cause vasodilatation (for review see 
Barnes and Liu, 1995). However controversy still exists over the roles 
of PGI2 and NO in HPV.
The failure, to date, to identify a single chemical mediator has 
promoted the alternative proposal that HPV may be caused by a direct 
effect of hypoxia on the pulmonary vascular muscle cells. In support 
of this hypothesis, small pulmonary arteries of the cat and human have 
been shown to contract in response to hypoxia in vitro (Madden et al.,
1985; Hoshino et al., 1988). Cultured isolated pulmonary artery 
smooth muscle cells also contract in response to hypoxia (Murray et 
al., 1990). Several mechanisms have been proposed to account for 
the direct action of hypoxia on smooth muscle cells. One such 
mechanism is that hypoxia leads to the closure of an oxygen-sensitive 
potassium channel, leading to smooth muscle depolarisation, Ca2+ 
entry, and contraction (Lopez-Lopez et al., 1989; Osipenko et al.,
1995). To date their are several proposed methods for regulation of a 
potassium channel by hypoxia, including redox-based modulation of 
potassium channels by the amount of oxygen radicals present. The 
free radicals present in the lung act to regulate the ratios of reduced to 
oxidised glutathione and pyridine nucleotides, which in turn contribute 
to the redox status of the whole cell (Kozlowski, 1995).
A second redox hypothesis suggests that oxygen tension within the 
cell regulates the production of reactive oxygen species, which control 
transmembrane Ca2+ flux and hence cell contractility through an action 
on sulfhydryl groups in the calcium channel within the cell membrane 
(Archer et al., 1986).
A third hypothesis is the membrane-delimited pathway of oxygen 
regulation of potassium channels. This theory states that molecular 
oxygen binds to the channel and is responsible for the open state of 
the channel. Removal of the oxygen during hypoxia results in closure 
of the channel, depolarisation and contraction (Lopez-Barneo, 1994).
13
With the onset of hypoxia, the amount of oxygen available for oxidative 
phosphorylation is reduced, thus reducing the amount of ATP 
produced. This would lead to the opening of K a t p  channels, which 
would hyperpolarise the cell and prevent contraction. This does not 
happen, as it has been shown that endothelial cells are capable of 
maintaining 75-80% of normoxic levels of ATP production and the 
same degree of protein synthesis (Pinsky etal., 1995).
The energy state hypothesis suggests that HPV is initiated by 
decreased oxidative phosphorylation (Rounds and McMurtry, 1981). 
The cytochrome P450 hypothesis proposes that cytochrome P450 acts 
as the oxygen sensor, detecting a fall in PO2 and initiating HPV (Miller 
and Hales, 1979).
The possible mechanisms responsible for phase 1 and phase 2 HPV 
have been explored and documented, although the link from the 
detection of the fall of PO2 to the regulation of the levels of constrictor / 














Figure 1.1. Possible mechanisms for hypoxic pulmonary 
vasoconstriction. Pulmonary vascular tone may increase as a result of 
release of vasoconstrictor substances, decreased vasodilator 
substances, or direct action of hypoxia on the vascular smooth muscle 
cells. Endothelin-1, ET-1; Nitric oxide, NO; Angiotensin-I, A I; 
Angiotensin-ll, A II; Calcitonin gene related peptide; CGRP (from 
Barnes and Liu, 1995).
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MODELS FOR INVESTIGATION OF HPV
Several methods have been used to investigate HPV, ranging from 
isolated cells to whole animal studies. Cultured isolated pulmonary 
artery vascular smooth muscle cells have been demonstrated to 
contract in response to hypoxia (Murray et al., 1990). Pulmonary 
artery rings from the rat, rabbit, cat, pig, calf, sheep and human have 
also been demonstrated to contract in response to hypoxia (for review 
see Wadsworth, 1994). However the response to hypoxia is variable, 
with responses ranging from rapid contraction (Rodman et al., 1990), a 
gradual rise in tone (Yuan et al., 1990) or a biphasic response (Bennie 
et al., 1991; Mathew et al., 1991). This may be due to the type of 
vessel used, with studies using both large conductance arteries (Yuan 
et al., 1990) and small resistance arteries (Demiryurek et al., 1991). A 
second possibility for the difference in the responses seen may be due 
to the variation in the distribution of various receptor types and ion 
channels within different regions of the vasculature.
Isolated perfused lungs have also been widely utilised for the study of 
HPV (Hauge et al., 1966; Hauge, 1968; Berkov, 1974; Marshall and 
Marshall, 1983; Marshall, 1984). The intact whole lung has the 
attributes for the investigation of HPV, as the entire vasculature is 
intact and in contact with other tissue types which may play a role in 
the development of the responses seen. Studies in vivo have mainly 
been used to examine the effects of long term hypoxia and the
16
subsequent pulmonary vascular remodelling and right ventricular 
hypertrophy. In addition to this, the vascular reactivity of pulmonary 
vessels has been investigated in animals exposed to chronic hypoxia 
(Emery etal., 1981).
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ISOLATED PERFUSED RAT LUNGS
The isolated perfused lung preparation has been reviewed several 
times in recent years (Mehendale, 1981; Njemeier, 1984; Marshall, 
1984; Bhattacharya, 1989). Depending upon the experimental 
requirements, the lung may be perfused with whole blood, plasma, or 
a plasma and blood free physiological salt solution (for review see 
Czartolomna et al., 1991; Chang and Voelkel, 1992; Rodman et al., 
1992). Blood perfused lungs closely resemble the in vivo state, and 
are utilised in a whole range of experiments, including the investigation 
of HPV. However these experiments can be costly, due to the volume 
of blood required (approximately 30-50 ml) for recirculation in each 
experiment. This may involve the use of several donor animals in the 
case of small animals such as rats. In addition to this anti-coagulants 
have to be used, which may interfere with the responses seen. The 
use of whole blood as a perfusate may also complicate interpretation 
of the results, as many substances (for example: eicosanoids and their 
metabolites, lipid mediators etc...) may bind to plasma proteins and/or 
be metabolised by cells in the recirculating blood. In single pass 
experiments, a large volume of perfusate is required, making the use 
of whole blood impractical.
For studies involving single pass perfusion, the use of a physiological 
salt solution (PSS) is recommended (Chang and Voelkel, 1992). This 
technique offers several advantages, as PSS perfusion lacks the
18
components of the blood which can cause the problems mentioned 
above. In addition, the composition of the perfusate can be precisely 
regulated, also the lung can be easily lavaged and microscopically 
examined.
A number of in situ and in vitro methods have been developed to 
perfuse and ventilate lungs (Levey and Gast, 1966; Kroll et al., 1986; 
Niemeier, 1984; Ryrfeldt et al., 1990; Uhlig and Wolin, 1994). The 
isolated lung, when perfused via the pulmonary artery, has been used 
to assess the release of substances from the lung in response to 
administration of a number of substances (Bakhle and Vane, 1974; 
Said, 1979; Robinson and Hoult, 1980; Bakhle et al., 1985; Peers and 
Hoult, 1986; Conroy e ta i, 1992).
Lungs perfused in a retrograde fashion via the pulmonary vein have 
also been utilised to study the actions of various vasoactive 
compounds, which may act upon the venous circulation (Lai et al., 
1994). Isolated lung preparations have also been used to investigate 
the actions of various compounds upon bronchial muscle tone (for 
review see Lou, 1993). However the effects of these compounds on 
both pulmonary vessels, bronchial resistance and permeability within 
the lung are rarely investigated together (Kroll et al., 1986; Ryrfeldt et 
al., 1990).
Permeability changes within the vasculature in response to hypoxia 
are not fully understood. Methods to investigate this phenomenon 
include using cultured endothelial monolayers (Horgan et al., 1991; 
Rodman et al., 1992). However the use of a cultured monolayer of 
endothelial cells obtained from one distinct area of the pulmonary 
vasculature cannot represent the whole pulmonary circulation which is 
an important part of vascular reactivity. In addition to this a whole lung 
can be used, this has an advantage over the use of cultured 
monolayers as there is an intact pulmonary endothelium and alveolar 
epithelium in a physiological setting (Czartolomna et al., 1991; Horgan 
et al., 1991; Seale eta!., 1991).
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PULMONARY FLUID BALANCE AND OEDEMA FORMATION
Formation of oedema within the lung can be regulated in several ways 
which are explained below.
The movement of fluid across the capillary endothelium is described 
by the Starling equation:
Q f =  Kf (Pcap " Pis) " " TCis)
Where Qf is the net flow of fluid; Kf is the capillary filtration coefficient; 
Pcap is capillary hydrostatic pressure; PjS is the hydrostatic pressure of 
the interstitial fluid; a is the reflection coefficient; 7Cpi is the colloid 
osmotic pressure of the plasma and 7ijS is the colloid osmotic pressure 
of the interstitial fluid.
The equation can be represented schematically (see Figure 1.2), and 
demonstrates the potential causes of pulmonary oedema, which 
include: an increase in the permeability of the capillary endothelium; 
an increase in the capillary hydrostatic pressure; a decrease in the 
interstitial hydrostatic pressure; an increase in the interstitial colloid 
osmotic pressure or lymphatic insufficiency (Levitzky, 1982). However 
in the pulmonary circulation plasma colloid pressure is usually greater 
than capillary hydrostatic pressure, and so there is little bulk fluid 







Figure 1.2. Schematic representation of the Starling equation 
describing the factors affecting liquid movement in and out of the 
pulmonary capillary. Pcap is capillary hydrostatic pressure; PjS is the 
hydrostatic pressure of the interstitial liquid; Tipi is the colloid osmotic 
pressure of the plasma and jCjS is the colloid osmotic pressure of the 
interstitial fluid (modified from Levitzky, 1982).
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The Starling equation states the laws governing fluid movement across 
a membrane, but other additional pathways for water and solute 
movement have been suggested (Staub, 1974). These include 
movement across cell membranes; movement through intercellular 
junctions and non-selective leak. Pores crossing cell membranes are 
water filled channels 4-5 A radius and only allow water to cross the 
membrane. The major site of ultrafiltration and protein flow is probably 
via the intercellular junctions (> 1000 A radius; Staub, 1974).
23
ENDOTHELINS
Endothelins are potent vasoactive peptides, first described by Hickey 
et al., (1985). This endothelial-derived constricting factor (EDCF) was 
then isolated from the culture medium of bovine aortic endothelial 
cells, purified, sequenced and cloned and renamed endothelin (ET) by 
Yanagisawa etal., (1988).
It was subsequently demonstrated that this ET was one of a family of 
21 amino acid vasoactive peptides, designated ET-1, ET-2 and ET-3, 
which have been shown to be encoded by three distinct genes. The 
ETs all contain four cysteine residues (positions 1,3,11 and 15), which 
participate in disulphide bond formation (Cys1-Cys11; Cys3-Cys15; Inoue 
et al., 1989). The peptides also have the same amino acids at 
positions 8, 10, 20 and 21. ET-1 is the isoform originally identified 
from bovine aortic endothelial cells (originally termed porcine 
endothelin). ET-2 differs by two amino acids from ET-1, and from ET- 
3 by six amino acids (see Figure 1.3). In addition to these peptides, a 
fourth peptide has been discovered following genomic cloning in mice 
(Saida etal., 1989), and termed vasoactive intestinal contracting factor 
(VIC) or endothelin-p. This has subsequently been found to be the 
murine and rat homolog of human ET-2 (Fabbrini etal., 1991).
The three ET isopeptides share a remarkable resemblance, both in 
structure and biological activity, to the sarafotoxins (Sx), a family of
24
peptides isolated from the venom of the snake Atractaspis 
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Sarafotoxin 6C
Figure 1.3. Structures of the Endothelins and Sarafotoxin 6C. 
Shaded amino acids indicate differences from endothelin-1.
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ENDOTHELIN BIOSYNTHESIS
The biosynthetic pathway for ETs follows a similar pattern to other 
peptide hormones and neurotransmitters. ETs are produced by the 
processing of precursor peptides. These peptides are termed 
preproendothelins -1,-2 and -3, which consist of approximately 200 
amino acids. The preproendothelins undergo cleavage to produce 38 
or 39 amino acid peptides known as big ETs. The big ET is then 
cleaved between positions Trp21 and Val22 by a specific endopeptidase 
known as endothelin converting enzyme (ECE; see Figure 1.4).
The chemical nature of ECE still remains a mystery, although two 
distinct forms have been separated. The first, termed M1 or ECE-1, is 
a membrane bound enzyme sensitive to phosphoramidon (IC50 = 
approximately 1pM), although not to thiorphan or bacitracin, and 
shows a pH optimum of 7.0. This ECE is associated with the plasma 
membrane and appears to convert big ET-1 to ET-1 more efficiently 
than big ET-2 or big ET-3 (Xu et a/., 1994). The other enzyme activity 
is termed M2, or ECE-2 and is reported to be associated with the Golgi 
apparatus, and shows an increased sensitivity to phosphoramidon 
(IC50 = approximately 0.3nM), and could also be inhibited by thiorphan 
and bacitracin, and has a lower pH optimum of 5.5. This enzyme 
cleaved both big ET-1 and big ET-2, but not big ET-3 (Emoto and 
Yanagisawa, 1995). It has been proposed that the M1/ECE-1 form of 
the enzyme represents the previously described vascular endothelial
ECE and is responsible for both intra-cellular and extra-cellular 
conversion of big ETs to the mature peptides, and that M2/ECE-2 form 
is the neutral endopeptidase EC 3.4.24.11 that is found in lung, kidney 
and may be the major ECE in neurones, glia and certain 
neuroendocrine cells (Goto et a!., 1996), and is thought to be 
responsible for the intracellular conversion of big ETs. M1/ECE-1 is 
thought to be more similar to the physiologically relevant ECE 






1 17-18 52-53 73-74 90-91 108-109 119-120
NH,




Phosphoramidon ^P"Endothelin Converting Enzyme 
p S 9 S S L M D K E C f V Y F ( j : H L D I I W
COOH
COOH
Figure 1.4. Schematic representation of the synthesis of human ET-1
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ENDOTHELIN RECEPTORS
The endothelin family of peptides have been shown to exert a wide 
variety of biological actions, which are thought to be mediated through 
specific membrane receptors. Two endothelin receptors had been 
cloned and reported by the end of 1990 (Arai et al., 1990; Sakurai et 
al, 1990). The first was isolated from a bovine cDNA library, and upon 
expression in Xenopus oocytes showed a greater affinity for ET-1 and 
ET-2 over ET-3. This was termed the ETa receptor. The second was 
isolated from a rat cDNA library and showed equal affinity for ET-1, 
ET-2 and ET-3. This was termed the ETb receptor. Following the 
cloning of the ETA and ETb receptors from non-human cDNA libraries, 
human forms of the receptors have been identified, and the rank order 
of potency of the ET isoforms confirmed, with ET-1 being 
approximately 1000 fold more potent than ET-3 on the ETA receptor 
(Hosoda et a l, 1991) and the lack of selectivity of the ET isoforms for 
the ETb receptor (Nakamuta e ta l, 1991; Sakamoto e ta l, 1991).
Functional studies however have suggested the existence of more 
than two receptor subtypes. The most widely proposed of these is the 
ETc receptor, which has been cloned from Xenopus leavis dermal 
melanophores. This receptor reportedly shows selectivity for ET-3 
over ET-1. This receptor has been shown to have approximately 50%  
amino acid homology with the ETA and ETb receptors (Karne et a l,
1993) In addition to the ETA, ETB and ETc receptors a fourth receptor,
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the E T a x  receptor has been cloned from Xenopus heart, and has been 
shown to share 74%, 60% and 51% amino acid homogeneity with 
human ETA and ETB receptors, and the Xenopus ETc receptor, 
respectively (Kumar etal. 1994).
In addition to the main types of receptors mentioned above, further 
divisions of the ETA and ETb receptors have been made. ETA 
receptors have been subdivided into ETAi and ETa2 receptors, where 
the former are BQ123 sensitive, and the later are BQ123 insensitive 
(Sudjarwo et al., 1994; Yoneyama et al., 1995). However, selective 
antagonists to ETAi and ET&  are not yet available, and so 
identification of these receptors is solely made upon the selective 
antagonism of ET-1 induced responses, either in preparations more 
sensitive to ET-1 than ET-3, or where selective ETb agonists are 
inactive (Bax and Saxena, 1994).
The ETb receptor was originally thought to mediate vasorelaxation, 
however the contraction of rabbit saphenous vein was shown to be 
mediated by ETb receptors (Moreland et al., 1992). From this, ETb 
receptors have been subdivided into two types, ETb i, located on the 
endothelial cells and mediating vasorelaxation through the release of 
nitric oxide (NO), and ETB2 receptors, located directly upon the 
vascular smooth muscle and mediating vasoconstriction (Sudjarwo et 
al., 1993; Warner etal., 1993a; Warner etal., 1993b).
31
RECEPTOR COUPLING
Endothelin receptors belong to the superfamily of seven 
transmembrane domain-spanning receptors linked to G-proteins (for 
review see Davenport et al., 1995). Endothelin receptors are coupled 
to several intracellular messengers which act to produce a wide variety 
of intracellular effects (see Figure 1.5). The major signal transduction 
pathway for the endothelin receptors has been established as 
activation of phosphatidylinositol 4,5-bisphosphate (PIP2)-specific 
phospholipase-C (PLC). Activation of PLC by endothelins leads to the 
cleavage of membrane bound phosphoinositides into inositol 1,4,5- 
trisphosphate (IP3) and diacylglycero! (DAG). Each of these second 
messengers then subsequently activates separate signal transduction 
pathways. DAG activates protein kinase C (PKC), and IP3 binds to a 
high affinity receptor on the endoplasmic reticulum and triggers the 
rapid mobilisation of Ca2+ (Sokolovsky, 1995). This increase in [Ca2+]j 
can activate Ca2+ dependent protein kinases, in addition to Ca2+- 
sensitive PLC and phospholipase-A2 (PLA2), which leads to the 
























Figure 1.5. Schematic representation of some of the signal
transduction pathways associated with activation of the endothelin 
receptor. DAG, diacylglycerol; IP3 , Inositol 1,4,5-triphosphate; LT, 
leukotriene; LX, lipoxin; PA, Phosphatidic acid; PG, prostaglandin; 
PKC, protein kinase C; PLA2, phospholipase A2, PLC,




Both selective and non-selective antagonists for ETA and ETB 
receptors have been developed (see Figure 1.6). The best known of 
the ETa receptor antagonists is the cyclic pentapeptide BQ123 (lhara 
et al., 1992; see Figure 1.7). This compound was isolated from the 
fermentation broth of the bacteria Streptomyces misakiensis. A 
sulphonamide derivative BMS 182874 has been described (Webb et 
al., 1995), as a potent orally active ETA selective receptor antagonist.
Selective ETb receptor antagonists have also been developed. These 
include BQ788 (Ishikawa et al., 1994; see Figure 1.7), RES-701-1 
(Karaki etal., 1994) and IRL1038 (Urade etal., 1992).
In addition, non-selective mixed ETa/ETb receptor antagonists have 
been described, including bosentan (Clozel et al., 1994; see Figure 
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Figure 1.6. Location of the putative endothelin receptors and the 
agents which act upon them. Shaded blocks contain antagonists 










Figure 1.7. Structure of a) the endothelin ETA receptor antagonist 
BQ123; b) the endothelin ETb receptor antagonist BQ788; and c) the 
mixed ETa/ETb receptor antagonist bosentan (sodium salt).
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PHARMACOLOGICAL ACTIONS OF ENDOTHELINS
Endothelins and sarafotoxins produce wide and diverse actions in both 
vascular and non-vascular smooth muscle (for reviews see Rubanyi 
and Polokoff, 1994; Levin, 1995). In the conscious rat, bolus 
administration of ET-1 causes a transient fall, followed by a prolonged 
increase in mean arterial blood pressure (Bird et al., 1993; Filep et al., 
1993; McMurdo et al., 1993). In isolated vessels, ET-1 causes 
contraction in both humans and animals, with a threshold of 
approximately 100 pM (Highsmith etal., 1992) These contractions are 
mediated by both ETA and ETB receptors, and the responses can be 
blocked by the mixed ETa/ETb receptor antagonist bosentan (Seo et 
al., 1994; White etal., 1994).
Endothelins can also elicit relaxation of pre-constricted vessels via 
activation of ETbi receptors, and the subsequent release of nitric-oxide 
(NO; Namiki et al., 1992; Karaki et al., 1993; Shetty et al., 1993; 
Zellers et al., 1994). Loesch and Burnstock (1995) have shown co­
localisation of endothelin and nitric oxide synthetase (NOS) in 
endothelial cells from pulmonary and coronary arteries of new-born 
rats, and such ET/NO release may play an important role in the 
vasoregulation of the cardiac and pulmonary circulations. In addition 
to actions on the vasculature, endothelins are also potent constrictors 
of airway smooth muscle in both the bronchus and trachea (see 
Rubanyi and Polokoff, 1994). ET-1 has also been shown to promote
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vascular and cardiac muscle proliferation and is a potent stimulator of 
DNA synthesis (see Barnes, 1994).
Endothelins are also oedemagenic in some vascular beds, including 
the bronchial circulation (Kurose etal., 1993; Filep et al., 1995, Lai et 
al., 1995). However controversy still exists over the oedemagenic 
nature of endothelins in the pulmonary circulation, with some 
investigators finding ET-1 infusion augmenting albumin escape into the 
lung (Lehoux et al., 1992; Zimmerman et al., 1992) or raising the 
pulmonary vascular fluid filtration rate (Barnard et al., 1991; Helset et 
al., 1993). Other investigators have found no evidence that ET-1 by 
itself increases pulmonary vascular permeability to protein (Macquin- 
Mavier et al., 1989; Rodman et al., 1992; Sirosis et al., 1992; Filep et 
al., 1995) or pulmonary vascular fluid filtration coefficient (Barnard et 
al., 1991; Horgan et al., 1991). In addition to this, ET-1 does not 
augment albumin movement across cultured endothelial monolayers 
(Horgan etal., 1991; Rodman etal., 1992).
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PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL ROLES OF  
ENDOTHELINS
Endothelins have been postulated to be involved in the maintenance 
of basal vascular tone (Rubanyi, 1989); regulation of water balance 
(for review see Rubanyi and Shepherd, 1992); to have local and 
systemic roles in haemorrhage; and paracrine-, autocrine- and 
endocrine signalling (for review see Rubanyi and Polokoff, 1994).
Pathological conditions thought to involve endothelins include: 
coronary vasospasm (Matsuyama etal., 1991; Toyo-oka etal., 1991); 
cerebral vasospasm following sub-arachnoid haemorrhage (Mosaoka 
et al., 1989; Lam et al., 1991); Raynaud’s disease (Zamora et al.,
1990); pre-eclampsia (Taylor et al., 1990; Clark et al., 1992); 
myocardial ischaemia (Yasuda etal., 1990; Lam et al., 1991); cerebral 
ischaemia (Ziv et al., 1992); congestive heart failure (Lerman et al., 
1992; Stewart et al., 1992; Tsutamoto et al., 1994); shock syndrome 
(including septic shock, cardiogenic shock and haemorrhagic shock; 
see Rubanyi and Polokoff, 1994); bronchial asthma (Mattoli et al.,
1991); gastric ulceration (Peskar et al., 1992); inflammatory bowel 
disease (Murch et al., 1992); renal insufficiency and chronic renal 
failure (Koyama et al., 1989; Warrens et al., 1990; Deray et al., 1992); 
hepatorenal syndrome (Uchihara et al., 1992) and pulmonary 
hypertension and hypoxic vasoconstriction (Levy et al., 1990; Stewart 
etal., 1991).
39
The evidence for the involvement of ETs in pulmonary hypertension 
and pathological conditions that result in a reduction of pulmonary 
oxygen tension comes from several studies showing increased levels 
of ET-1 following hypoxia exposure, both in animals and humans.
Several animal models of pulmonary hypertension have been used to 
demonstrate elevated levels of ET-1. These models include idiopathic 
pulmonary hypertension in fawn hooded rats, where elevated plasma 
and lung levels of ET-1 were demonstrated, compared to normal 
control animals (Stelzner et al., 1992), and monocrotaline-induced 
pulmonary hypertension in beagles, where plasma ET-1 levels 
increase by up to threefold in this form of chronic pulmonary 
hypertension (Okada etal., 1995).
Further evidence for the involvement of ETs in pulmonary 
hypertension comes from studies utilising the ET receptor antagonists. 
Several studies have shown that the ET receptor antagonists BQ123 
and bosentan can both prevent and halt the progression of the 
physiologic and morphologic changes that arise from exposure to 
chronic hypoxia (for review see Michael and Markewitz, 1996). In 
addition to this, it has been reported that BQ123 can prevent the rise 
in pulmonary artery pressure in rats exposed to hypoxia for a period of 
90 min (Oparil etal., 1995).
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It has been shown that plasma levels of ET-1 are increased in patients 
with pulmonary hypertension associated with many different diseases, 
including primary pulmonary hypertension (Cacoub et al., 1993); 
hypoxic lung disease (Stewart et al., 1991); collagen vascular disease 
(Vancheeswaran etal., 1994) and congestive heart failure (Cody etal.,
1992). One of the first studies showed an approximate six fold 
increase in plasma ET-1 levels in four patients with pulmonary 
hypertension (controls: 0.26 ± 0.24 pg/ml, n=14 vs 1.52 ± 0.45 pg/ml, 
n=4, p<0.001, Cernacek and Stewart, 1989). In addition to this, 
studies have shown a correlation between plasma ET-1 levels and the 
degree of increase in mean pulmonary artery pressure during hypoxia 
(Allen et al., 1993). This study also demonstrated that there was no 
difference in the ET-1 levels in patients with chronic cardiopulmonary 
disorders without pulmonary hypertension.
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PROJECT AIMS
(a) To develop a single pass hypoxic lung model, that allowed 
measurement of pulmonary perfusion pressure, pulmonary inflation 
pressure and lung weight.
(b) To investigate the role of endothelins in the responses to hypoxia 
in the lung.
(c) To develop a recirculating lung model that responded in the same 
way as a single pass model to hypoxia.
(d) To measure the release of ET-1 into the perfusate under both 
normoxic and hypoxic conditions.
(e) To measure prepro endothelin-1 mRNA levels within the lung 
following normoxic and hypoxic perfusion.
(f) To investigate the responses of the lung to exogenous ETs in the 






Male Wistar rats (310 - 340g) were supplied by the University of Bath 
Animal House.
DRUGS AND CHEMICALS
Drugs and chemicals used were obtained from the following sources:







Big endothelin-1, Endothelin-1, Endothelin-3, Sarafotoxin 6C 
Perkin Elmer (Applied Biosystems), Warrington:
10XPCR buffer II, Agarose, MgCl2 , Taq polymerase 
Pharmacia Biotech, St Albans:
100 bp ladder, dATP, dCTP, dGTP, dTTP, dUTP, Oligo d(T)12-i8 
primer, QuickPrep Micro mRNA purification kit
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Promega, Southampton:
5x RT-buffer, M-MLV reverse transcriptase, RNAsin 
R&D Systems, Abingdon:
Human ET-1 ELISA 
Rhone Merieux LTD, Harlow:
Pentobarbitone sodium (Sagatal)
Sigma Chemical Company, Poole:
Acetylated bovine serum albumin, L-Arginine, Bovine Serum Albumin, 
Bradykinin acetate, Bromophenol blue, Colchicine, Cycloheximide, 
Ethidium bromide, Formamide, Gel loading buffer, Heparin Sulphate, 
Noo-nitro-L-Arginine, Nonitro-L-Arginine methyl ester, Phalloidin, 
Xylene cyanole FF
All other reagents were of analytical grade, and supplied by BDH, 
Poole; Fisons, Loughborough and Sigma Chemical Company, Poole.
The following compounds were kindly supplied by Drs A.G. Roach and 
T.J. Brown, Rhone-Poulec Rorer (Dagenham, England):
BQ123 (cyclo-[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]), BQ788 (N-cis-2,6- 
dimethylpiperidinocarbonyl-L-YMeLeu-D-Trp(COOMe)-D-Nle-ONa) and 





A Krebs-Henseleit solution of the following composition (mM) was 
used: potassium chloride 4.7, potassium dihydrogen phosphate 1.2, 
calcium chloride 1.25, magnesium sulphate 1.2, sodium chloride 118, 
sodium bicarbonate 25, and glucose 11.1, pH 7.4. The Krebs solution 
was gassed with either 20%02/5%C02/75%N2 (normoxic) or 
95%N2/5% C 02 (hypoxic).
HEPARIN SOLUTION
Heparin sulphate (bovine) was dissolved in 0.9 % w/v saline to give 
1000 IU ml'1. Aliquots were stored at 4°C until use.
All other compounds were dissolved in sterile saline unless otherwise 
stated.
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ISOLATED VENTILATED PERFUSED RAT LUNG
Lungs were isolated and perfused as described previously (Lai et al.,
1994). Male Wistar rats (310-340g) were anaesthetised with sodium 
pentabarbitone (100 mg/kg i.p.). Heparin (500 IU) was then 
administered i.v. via the tail vein; 5 min later the chest was opened and 
the pulmonary artery cannulated with a stainless steel cannula via the 
right ventricle. The left atrium and main mass of the ventricles were 
removed to allow free efflux of the perfusate. The trachea was 
cannulated and the lungs removed and placed in a warming jacket at 
37°C. Lungs were perfused via the pulmonary artery at a constant 
rate of 5 ml min'1 with a Krebs-Henseleit solution, gassed with either 
20% 02/5%C02/75%N2 (normoxic) or 95%N2/5%C02 (hypoxic). All 
ventilation and perfusion tubing was of the low gas permeability type 
(Tygon R3603 and PharMed 65). Pulmonary perfusion pressure 
(PPP) was recorded via a pressure transducer (Druck model PDCR) 
connected to the pulmonary arterial cannula. The tracheal cannula 
was connected to a ventilator (Harvard miniature animal ventilator) and 
lungs were ventilated with room air at a stroke volume of 1ml and a 
rate of 28 inflations/min (with no positive end expiratory pressure). A 
pressure transducer (Druck model PDCR) attached to the tracheal 
cannula facilitated measurement of pulmonary inflation pressure (PIP). 
In addition lungs were suspended from a force displacement 
transducer (Dynamometer UF-1) for continual measurement of lung 
weight (see Figure 2.1). All responses were recorded on a Lectromed
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MX6 pen recorder. Both normoxic and hypoxic control experiments 
were performed throughout the duration of the studies. Lungs were 
allowed to stabilise for 15 min prior to the start of the experiment.
isometric transducer (A LW)
(PIP) trachea












Figure 2.1. Schematic representation of the isolated, ventilated, 
perfused rat lung. LW, lung weight; PIP, pulmonary inflation pressure; 
PPP, pulmonary perfusion pressure.
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AGONIST AND ANTAGONIST STUDIES
In a series of experiments the effects of a series of agonists was 
investigated. The lungs were allowed to stabilise for a period of 30 
min. Then the agonist was administered via the pulmonary artery 
cannula in a bolus dose not exceeding 50 pi. The response was 
allowed to stabilise prior to administration of any subsequent dose.
In some experiments antagonists were added to the perfusate 15 min 
prior to agonist administration, and were present for the duration of the 
experiment.
HYPOXIA STUDIES
In a series of experiments the effect of systemic hypoxia on the lung 
was investigated. Two types of protocol were used, a single pass and 
a recirculating system.
Single-pass perfusion
Following the initial stabilisation period perfusion continued for a 
further 15 min prior to the onset of hypoxia. Hypoxia was initiated by 
switching to a Krebs-Henseleit solution previously equilibrated with 
95%N2/5%C02. In studies involving drug treatment, the drug was 
perfused for 15 min prior to the onset of hypoxia and for the remainder
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of the hypoxic period (70 min). During the 15min pre-treatment period 
none of the agents used had any effect on basal PPP or LW. Control 
experiments (both normoxic and hypoxic) were performed throughout 
the duration of the study.
Recirculating perfusion
Following 15 min stabilisation, lungs were perfused in a recirculating 
manner (recirculating volume 50 ml) under normoxic conditions for a 
further 15 min. The lungs were then exposed to hypoxia by switching 
the gas mixture from 20%02/5%C02/75%N2 to 5%C02/95%N2. In 
studies involving drug treatment, the drug was added to the 
recirculating Krebs solution at the start of recirculation period. In 
keeping with the single pass perfusion study, control experiments 
(both normoxic and hypoxic) were performed throughout the duration 
of the study.
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MEASUREMENT OF OXYGEN TENSION
In some experiments oxygen tension was measured in the perfusate 
entering and leaving the lung. The perfusate was pumped through a 
Clarke type oxygen electrode, calibrated to express PO2 in mmHg. 
The electrode was calibrated with distilled water, which had been 
gassed with room air for 30 mins, to a PO2 calculated from the 
following equation:
PO2 (mmHg or Torr) = - x (b - vp)
Where b is the barometric pressure in mmHg, from a 
barometer, and vp is the water vapour pressure at any given 
temperature.
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ALBUMIN BOUND DYE EXTRAVASATION
Evans Blue dye was added to a 10% w/v solution of bovine serum 
albumin to give a final concentration of 1 mg ml'1. The mixture was 
dialysed overnight in 22/32 Visking tubing against an excess of distilled 
water. The albumin bound Evans Blue was then infused into the 
pulmonary artery at 50 \i\ min'1 for a 5 min period during the 
experiment. Following infusion, the lungs were perfused for a further 
15 min to remove any remaining dye from the vasculature. Lungs 
were then dried overnight in an oven at 80°C. The trachea was then 
removed, and the weight of the main mass of the lungs recorded. 
Lungs were then digested in 5 ml formamide at 37°C for 20 hours. 
The formamide was then removed, and centrifuged (6000 xg, room 
temperature, 30 min; IEC Centra-M). The absorbance of standard 
concentrations of Evans Blue (0.001 - 100 pg ml'1) or lung extracts 
were measured at 622 nm in a spectrophotometer (Pye Unicam, PU 
8610), against an appropriate formamide blank. The concentration of 
the dye in the lung extracts was calculated by reference to a standard 
curve of Evans Blue concentrations. From this the amount of Evans 
Blue retained in the lung could be calculated.
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ENDOTHELIN EXTRACTION
Endothelins were extracted from both perfusate samples and tissue 
samples. Two extraction procedures were used:
Perfusate extraction
ETs were extracted from the recirculated perfusate using a modified 
acetic acid extraction (Rolinski et ah, 1994). 25 ml of perfusate was 
acidified with glacial acetic acid to give a final concentration of 10% 
v/v, and the sample centrifuged (2500 xg, room temperature, 15 min).
Tissue extraction
ETs were extracted from tissue samples using a modified acetic acid 
extraction (Clerico et ai., 1994). Approximately 500 mg wet weight of 
tissue was homogenised in 5 ml 10% acetic acid (Ultra-Turrax, 20000 
rpm, 30 sec). The sample was then boiled for 10 min and allowed to 
cool to room temperature, and centrifuged to produce a clear 
supernatant (25000 xg, 30 min, 4°C).
The ET extraction from the perfusate and tissue samples then followed 
the same procedure. The supernatant was applied to a washed (3 ml 
methanol, 3 ml distilled water, 3 ml 10% v/v acetic acid) Amprep ethyl 
C2 minicolumn under negative pressure. The column was then 
washed with 3ml 10% v/v acetic acid and 6ml ethyl acetate. The ETs
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were eluted from the column with 3ml methanol : 0.05 M ammonium 
bicarbonate 80/20 v/v, and dried overnight in a vacuum oven.
ET-1 ASSAY
ET-1 was measured in an R&D Systems Human ET-1 ELISA. Dried 
samples were reconstituted in 250 pi sample buffer and ET-1 was 
quantitated with a R&D Systems Human ET-1 ELISA. Reconstituted 
samples were assayed within one hour, and assayed in duplicate and 
results measured on a plate reader (Titertek Multiskan MC340). The 
ELISA is sensitive to <1.0pg ml'1 ET-1 and shows <1% cross reactivity 
with big ET-1 and 14% cross reactivity with ET-3.
PROTEIN DETERMINATION
Protein levels were determined from the homogenised tissue samples 
using the Bradford method. Bovine serum albumin (1-10 mg/ml) was 
used to produce a standard curve.
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mRNA EXTRACTION
Total lung mRNA was extracted using a Pharmacia Biotech QuickPrep 
Micro mRNA purification kit.
REVERSE TRANSCRIPTION AND 1st STRAND cDNA SYNTHESIS
Reverse transcription (RT) of the isolated mRNA was performed to 
obtain cDNA for polymerase chain reaction (PCR) and analysis. 
Briefly, 2pl oligo d(T)i2-is primer (50 pM) was added to 20 ng poly(A+) 
mRNA in 10 pi sterile distilled water (SDW) and heated to 65°C for 10 
min, then allowed to cool to room temperature for 2 min and placed on 
ice. 8 pi of pre-prepared reaction mixture containing 4pl 5x RT-buffer 
(250 mM Tris-HCI pH8.3, 375 mM KCI, 15mM MgCh, 50 mMDTT), 1pl 
acetylated bovine serum albumin (2 mg ml'1), 1pl dNTPs (20mM, 1 
part each 100mM dATP, dCTP, dGTP, dUTP and 1 part sterile distilled 
water), 1pl RNAsin (20-40 U pi'1), 1pl M-MLV reverse transcriptase 
(200 U pi'1) was then added, and the reaction mixture was mixed by 
inversion and incubated at 37°C for 60 min. 40pl of sterile distilled 




The primer sets for rat prepro ET-1 mRNA were designed on PRIMER 
SELECT and LASER GENE (DNA Star, Wisconsin, USA). For the 
amplification of cDNAs the following primers were used. (3-actin: 
primer I, 5’-ccT Age Acc AAg AAg ATc AA-3’, primer II, 5!-TTT cTg ege 
AAg TTA ggT TTT gTc AA-3’, annealing temperature (AT) 50°C; rat 
prepro-endothelin-1: primer I, 5’-gAg gcc ATc Age AAc Age ATc A-3’, 
primer II, 5’-Tcc gAg gcc ATc ccc AgA c-3’, AT 58°C. Reactions were 
performed in 100 pi volumes containing 1xPCR buffer II, 1.5mM 
MgCI2, 200 pM dATP, 200 pM dCTP, 200 pM dGTP, 200 pM dTTP, 
0.4 pM primer I, 0.4 pM primer II, 2.5 U Taq polymerase and 5 pi of 
the RT reaction. The reaction mixtures were incubated at 94°C for 5 
min and then run for 31 cycles for the p-actin, and 35 cycles for the rat 
prepro-endothelin-1, at 94°C for 1min, AT for 1 min and 72°C for 2 
min, finishing with a 6 min incubation at 72°C in a Perkin Elmer DNA 
480 thermal cycler. Sterile distilled water controls were included with 
each batch of reactions.
Twenty microlitres of each PCR mixture was mixed with 2 pi gel 
loading buffer (0.042% w/v bromophenol blue; 0.042% w/v xylene 
cyanole FF; 6.7% w/v sucrose), and 14 pi electrophoresed on a 2% 




Increases in PPP and LW induced by hypoxia are expressed as actual 
recorded values recorded at set time points following the onset of 
hypoxia. Increases in PPP, PIP and LW induced by bolus injections of 
agonists are expressed relative to the basal values prior to the addition 
of each dose. Data were expressed as mean ± standard error of the 
mean (SEM). Data from control experiments was pooled for each 
series of experiments, and the pooled data used in the statistical 
analysis. Analysis of variance (ANOVA) followed by Newman-Keuls 
post-hoc test or Student’s (unpaired) t-test were used to test the level 







The use of the salt perfused isolated ventilated rat lung has been 
characterised previously (Lai, 1995). However the use of an isolated 
lung with a perfusate (systemic) hypoxia has not previously been 
examined.
P 02 DETERMINATION
The use of different types of tubing on the experimental apparatus led 
to the observation of changes in perfusate P 02, dependent upon not 
only the gas mixture used to gas the Krebs buffer, but also upon the 
tubing used. Standard PVC laboratory tubing (Portex) allowed 
diffusion of oxygen into the perfusate, thus altering the P 0 2 level 
between the Krebs reservoir and the lungs. To alleviate this problem 
low oxygen permeability tubing (Tygon R3060 and PharMed 65) was 
used, which minimised oxygen diffusion.
In addition to this, several perfusion/ventilation regimens were tried, 
the results of which can be seen in table 3.1. The arterial P 0 2 value 
equates to the P 0 2 of the Krebs in the reservoir prior to perfusion and 
the venous P 02 was measured in perfusate following efflux from the 
pulmonary vein.
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Room Air 580 165
O2/CO2
(95%/5%)
N2/CO2 Not Measured 60
N2/CO2
(95%/5%)
Room Air 15 100
N2/CO2
(95%/5%)
N2/CO2 Not Measured 5
N2/O 2/CO2
(75%/20%/5%)
Room Air 140 135
N2/O 2/CO2
(75%/20%/5%)
N2/CO2 Not Measured 40
The values obtained in the above table were determined during an 
initial series of experiments to determine the perfusion/ventilation 
regimen to be used. The values quoted in the text are taken from 
subsequent measurements made during the course of the study. The 
eventual regimen used involved gassing the Krebs with a 
75%/20%/5% mixture of N2/O2/CO2 for normoxic perfusion, as this 
provides a more physiological oxygen tension than a 95%/5% mixture 
of O2/CO2 . A 95%/5% mixture of N2/C 0 2 was utilised for the hypoxic 
perfusion. The lungs were ventilated with room air for all experiments. 
This resulted in P 0 2 levels (determined at the pulmonary arterial 
cannula) of 5.5 ± 1 .9  mmHg under a hypoxic conditions (95% N2 / 5% 
C 0 2) and 121 ± 7.3 mmHg under normoxic conditions (20% 0 2 / 5% 
C 0 2/75%  N2; n=3-6).
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SINGLE PASS PERFUSION 
Basal Parameters
Following the 15 min stabilisation period, under normoxic conditions, 
PPP was 6.54 ±0.16 mmHg and the increase in LW, over the 15 min 
stabilisation period, was 0.06 ± 0.01 g (n=72).
Effects of Hypoxia
In lungs perfused with normoxic Krebs solution, 70 min perfusion 
resulted in an increase in PPP from 6.6 ± 0.6 mmHg to 8.4± 0.5 
mmHg, and an increase in LW of 0.4 ±0.1 g (n=7). Neither of these 
changes were significant. However, in lungs which were perfused for 
70min with hypoxic Krebs solution, PPP increased from 8.2 ± 0.8 
mmHg to 15.4 ± 1.4 mmHg (n=10, p<0.001) and LW increased by 2.4 
± 0.6 g (n=10, p<0.001; see Figure 3.1 and Figure 3.2). The increase 
in PPP was slow and gradual. LW began to increase following 
approximately 30 min hypoxic perfusion, with an initial gradual 
increase followed by a rapid increase. Both of these changes are also 
significantly greater than those seen over the same time period in the 
control normoxic group (p<0.001). Over the time course of these 
experiments there was no significant difference in PIP in either 
normoxic or hypoxic lungs, therefore the data has been omitted.
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Figure 3.2. The effects of Normoxic and Hypoxic perfusion on 
Pulmonary Perfusion Pressure (PPP) and Lung Weight (LW) in the 
isolated ventilated perfused rat lung. n=7-10, * p<0.05; *** p<0.001 vs 
time-matched normoxic controls.
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EFFECTS OF INHIBITORY AGENTS ON HPV
(a) Prazosin
Prazosin (100 nM), at a concentration that was shown to block 
responses to 25 nmol phenylepherine, did not prevent the 
development of HPV in the lung. PPP increased by 5.5 mmHg (n=2) in 
prazosin treated lungs, compared to a 7.2 ± 1.4 mmHg (n=10) 
increase in the hypoxic control lungs. In addition to this the increase in 
lung weight observed in the prazosin treated animals was 4.6g, 
compared to an increase of 2.4 ± 0.6 g (n=10) in the hypoxic control 
over the same time period (results not shown).
(b) Indomethacin
Addition of indomethacin (3pM) to the perfusate 15 min prior to the 
onset of hypoxia resulted in the attenuation of hypoxia-induced 
increase in perfusion pressure. This was accompanied by a reduction 
in the hypoxia induced increase in LW, although this was not 
significant (see Figure 3.3).
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(c) Nitro-L-arainine. L-NAME and L-arginine
The nitric oxide synthetase inhibitors nitro-L-arginine (100pM) and L- 
NAME (100|xM) had no effect upon basal parameters following 15 min 
perfusion, and had no significant effect upon the hypoxia-induced 
increase in vascuiar resistance, however, L-NAME (100pM) 
significantly attenuated the increase in lung weight caused by hypoxia 
(from 2.4 ± 0.6 g to 0.51 ± 0.14 g, n=5-10, p<0.001; see Figure 3.4).
Addition of 500pM L-arginine to the perfusate, in the absence of nitro- 
L-arginine and L-NAME, resulted in an attenuation of the increase in 
vascular resistance following hypoxia from 15.4 ± 1 .4  mmHg to 9.6 ± 
1.7 mmHg (n=4-10, p<0.05; see Figure 3.4).
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Figure 3.3. The effect of 3 j i M  Indomethacin upon Hypoxia induced 
increases in Pulmonary Perfusion Pressure (PPP) and Lung Weight 
(LW) in the isolated ventilated perfused rat lung. n=4-10, ** p<0.01, 
*** p<0.001 vs time-matched hypoxic control.
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Figure 3.4. The effect of Nitro-L-arginine, L-NAME and L-arginine 
upon Hypoxia induced increases in Pulmonary Perfusion Pressure 
(PPP) and Lung Weight (LW) in the isolated ventilated perfused rat 
lung. n=4-10, * p<0.05; *** p<0.001 vs time-matched hypoxic controls.
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EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONISTS ON
RESPONSES TO HYPOXIA
To examine the involvement of the endothelins in the increase in 
vascular resistance and increase in lung weight following the onset of 
hypoxia, a variety of drugs which inhibit ET formation, secretion and 
actions were studied.
(a) BQ123
BQ123, an ETa receptor antagonist, at concentrations of 3pM and 
10pM, reduced the increases in PPP evoked by hypoxia from 15.4 ± 
1.4 mmHg to 7.8 ± 0.4 and 9.2 ± 0.8 mmHg, respectively (n=6-10, 
p<0.001). BQ123 also attenuated the hypoxia-induced increase in LW 
from 2.4 ± 0.6 g to 2.1 ± 0.4 and 1.0 ± 0.2 g in a concentration- 
dependent manner (n=6-10), however, when compared to time- 
matched hypoxic controls, this reduction in LW was only significant at 
the higher concentration used (p<0.01; see Figure 3.5).
(b) BQ788
BQ788, an ETb receptor antagonist, at a concentration of 3p,M, 
reduced the hypoxia-induced rise in PPP (from 15.4 ± 1 . 4  mmHg to 
9.6 ± 0.4 mmHg; n=5-10, p<0.01) when compared to time-matched 
hypoxic controls (see Figure 3.6). In addition BQ788 attenuated the 




The mixed ETa/ETb receptor antagonist bosentan (1.5 and 5 pM) also 
significantly attenuated the hypoxia-induced increases in LW from 2.4 
± 0.6 g to 0.85 ± 0.1 (1.5 pM) and 0.5 ± 0.1 g (5 pM; n=4-10, p<0.01) 
when compared to time-matched hypoxic controls. However, only the 
lower concentration of bosentan (1.5pM) produced a significant 
inhibition of the HPV (from 15.4 ± 1.4 mmHg to 9.0 ± 1.2 mmHg, n=4- 
10, p<0.05) when compared to time-matched hypoxic controls (Figure 
3.7).
EFFECTS OF AN ENDOTHELIN CONVERTING ENZYME INHIBITOR 
ON RESPONSES TO HYPOXIA
Phosphoramidon
As can be seen from Figure 3.8, the ECE inhibitor, phosphoramidon 
(1pM), significantly reduced both the hypoxia-induced vasoconstriction, 
from 15.4 ± 1.4 mmHg to 8.9 ± 0.8 mmHg (n=4-10, p<0.01), and 
increase in LW, from 2.4 ± 0.6 g to 1.1 ±0.3 g (n=4-10, p<0.05), when 
compared to time-matched hypoxic controls.
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Figure 3.5. The effect of BQ123 (3 and 10 |iM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=6-10, ** 
p<0.01; *** p<0.001 vs hypoxic control.
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Figure 3.6. The effect of BQ788 (3p,M) on Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) following hypoxic perfusion in 
the isolated ventilated perfused rat lung. n=5-10, * p<0.05; ** p<0.01; 
*** p<0.001 vs hypoxic control.
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Figure 3.7. The effect of Bosentan (1.5 and 5 p,M) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=4-10, * 
p<0.05; ** p<0.01; *** p<0.001 vs hypoxic control.
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Figure 3.8. The effect of Phosphoramidon (1jiM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=4-10, * 
p<0.05; ** p<0.01 vs hypoxic control.
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EFFECTS OF CYTOSKELETAL MODIFYING AGENTS ON
RESPONSES TO HYPOXIA
Phalloidin and colchicine
When compared to time-matched hypoxic controls, phalloidin (10 and 
50 nM), a f-actin stabiliser, and the microtubule-disrupting agent 
colchicine (100nM) attenuated the hypoxia-induced increases in PPP 
from 15.4 ± 1.4 mmHg to 8.8 ± 1.1, 9.9 ± 0.8 and 8.4 ± 0.6 mmHg, 
respectively, n=5-10, p<0.01, (see Figure 3.9). Colchicine, and the 
higher concentration of phalloidin, also significantly lowered the 
increases in LW from 2.4 ± 0.6 g to 0.7 ± 0.2 and 0.2 ± 0.1 g 
respectively (n=5-10, p<0.001, see Figure 3.10). In some experiments 
bradykinin (40 nmol, n=2 for both phalloidin and colchicine) was added 
prior to the addition of phalloidin and colchicine and at the end of the 
experiment to assess possible changes in vascular reactivity caused 
by these agents. In these experiments the increase in PPP elicited by 
bradykinin was the same at the start and end of the experiment (10.8 
vs 12.5 mmHg for phalloidin and 9.5 vs 14.0 mmHg for colchicine).
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EFFECTS OF A PEPTIDE SYNTHESIS INHIBITOR ON THE
RESPONSES TO HYPOXIA
Cvcloheximide
The protein synthesis inhibitor cycloheximide (5 pM) significantly 
lowered increases in PPP evoked by hypoxia, from 15.4 ± 1.4 mmHg 
to 6.9 ± 0.4 mmHg, and LW, from 2.4 ± 0.6 g to 0.65 ± 0.2 g (n=4-10, 
p<0.01), when compared to time-matched hypoxic controls (see Figure 
3.11).
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Figure 3.9. The effect of Phalloidin (10 and 50 nM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=5-10, * 
p<0.05; ** p<0.01; *** p<0.001 vs hypoxic control.
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Figure 3.10. The effect of Colchicine (100 nM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=5-10, * 
p<0.05; ** p<0.01; *** p<0.001 vs hypoxic control.
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Figure 3.11. The effect of Cycloheximide (5pM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated perfused rat lung. n=4-10, *** 
p<0.001 vs hypoxic control.
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EVANS BLUE DYE ACCUMULATION
To investigate the possible mechanisms involved in the change in LW 
seen following hypoxic perfusion, a series of experiments were 
performed utilising albumin bound Evans blue dye. With hypoxic 
perfusion, the increase in LW was associated with a large 
accumulation of Evans blue (29.6 ±6.1 ng mg'1 dry weight, n=6) when 
compared to time-matched normoxic controls (0.98 ± 0.09 ng mg'1 dry 
weight, n=5, p<0.01). Back-calculation of the fluid retention from the 
retained dye indicated that the lungs retained 1.7 ± 0.4 ml of fluid 
during the dye infusion (n=6). Assuming a specific gravity of 1.0, this 
does not differ significantly from the recorded increase in LW of 1.8 ± 






Figure 3.12. Actual changes in lung weight and back calculated fluid 
accumulation from Evans blue dye in Normoxic and Hypoxic isolated 
perfused rat lungs. n=5-6.
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RECIRCULATING PERFUSION
Following the demonstration of the involvement of endothelins in a 
single pass system, a recirculating system was devised from which the 
perfusate could be analysed for endothelin content. The experimental 
conditions for the single pass mode! were utilised and some of the 
perfusate samples collected and stored.
Basal Parameters
Following the 15 min stabilisation period, PPP was 6.8 ±0.17 mmHg 
and the increase in LW was 0.057 ± 0.007 g (n=60).
Effects of Hypoxia
Recirculating normoxic perfusion caused a fall in PPP from 7.4 ± 0.7 
mmHg to 7.1 ± 0.7 mmHg (n=7) following 85 min recirculating 
perfusion (see Figure 3.13). LW increased by 0.17 ± 0.05 g over the 
same period (n=7). Recirculation of a hypoxic perfusate resulted in an 
increase in PPP from 8.6 ± 0.6 mmHg to 11.4 ± 0.7 mmHg (n=7, 
p<0.05). This was accompanied by an increase in LW of 1.7 ± 0.7g 
(n=7, p<0.001, see Figure 3.14). The increase in vascular resistance 
was slow to develop and did not reach a plateau during the course of 
the experiment. LW began to increase after approximately 40 min 
hypoxia. As with the single pass experiments, there was no significant
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difference in PIP in either normoxic or hypoxic lungs, therefore the 
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Figure 3.14. The effect of Recirculating Normoxic and Hypoxic 
perfusion on Pulmonary Perfusion Pressure (PPP) and Lung Weight 
(LW) in the isolated ventilated perfused rat lung. n=7, * p<0.05; ** 
p<0.01; *** p<0.001 vs time-matched normoxic controls.
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EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONISTS ON
RESPONSES TO HYPOXIA
(a) BQ123
Addition of the endothelin ETa receptor antagonists BQ123 (10 pM) to 
the recirculating perfusate attenuated the hypoxia-induced increase in 
PPP from 11.4 ± 0.7 mmHg to 8.5 ± 0.4 mmHg (n=3-7, p<0.05; see 
Figure 3.15). In addition, BQ123 also reduced the rise in LW caused 
by hypoxic perfusion from 1.7 ± 0.7 g to 0.5 ± 0.01 g (n=3-7, p<0.05).
(b) BQ788
The endothelin ETb receptor antagonist BQ788 (3jliM) caused a 
significant reduction in both the hypoxia-induced increases in vascular 
resistance and lung weight from 11.4 ± 0.7 mmHg and 1.7 ± 0.7 g to 
7.8 ± 0.3 mmHg and 0.3 ± 0.1 g respectively (n=4-7, p<0.05 in both 
cases; see Figure 3.16)
(c) Bosentan
The mixed ETa/ETb receptor antagonist bosentan (1.5jiM) attenuated 
the hypoxia-evoked increases in PPP and LW, from 11.4 ± 0.7 mmHg 
to 8.1 ± 0.7 (n=4, p<0.05). In addition to this the hypoxia-induced 
increase in LW was also reduced by bosentan from 1.7 ± 0.7 g to 0.3 ± 
0.1 (n=4, p<0.01; see Figure 3.17).
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EFFECTS OF AN ENDOTHELIN CONVERTING ENZYME INHIBITOR
ON RESPONSE TO HYPOXIA
Phosphoramidon
Following 85 min recirculating perfusion in the presence of 1 pM 
phosphoramidon PPP was 7.6 ± 1.0 mmHg (n=6) vs 11.4 ± 0.7 mmHg, 
(n=7). In addition to this the increase in LW in the presence of 1 pM 
phosphoramidon was 2.8 ± 0.9 (n=6), when compared to the time- 
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Figure 3.15. The effect of BQ123 (10pM) on Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) following hypoxic perfusion in 
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Figure 3.16. The effect of BQ788 (3jiM) on Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) following hypoxic perfusion in 
the isolated ventilated recirculating perfused rat lung. n=6-7, * p<0.05; 
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Figure 3.17. The effect of Bosentan (1.5jiM) on Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) following hypoxic perfusion in 
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Figure 3.18. The effect of Phosphoramidon (1 i-lM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated recirculating perfused rat lung. 
n=6-7.
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EFFECTS OF CYTOSKELETAL MODIFYING AGENTS ON
RESPONSES TO HYPOXIA
Phalloidin and colchicine
When compared to time-matched hypoxic controls, the f-actin 
stabiliser phalloidin (50 nM) and the microtubule disrupting agent 
colchicine (100 nM) attenuated the hypoxia-induced increase in PPP 
from 11.4 ± 0.7 mmHg (n=7) to 7.4 ± 0.4 mmHg (n=4, p<0.01) and 8.8 
± 0.8 mmHg (n=5, p<0.05) respectively. Both the phalloidin and the 
colchicine significantly attenuated the hypoxia induced increase in LW 
from 1.7 ± 0.7g to 0.3 ± 0.08 mmHg and 0.3 ± 0.07 mmHg respectively 
(p<0.01, n=4-7, see Figures 3.19 and 3.20).
EFFECTS OF A PEPTIDE SYNTHESIS INHIBITOR ON THE 
RESPONSES TO HYPOXIA
Cycloheximide.
The protein synthesis inhibitor cycloheximide (5 fiM) significantly 
reduced the hypoxia induced increase in both PPP (7.0 ± 0.4 mmHg, 
p<0.001, n=4) and LW (0.3 ± 0.1 g, p<0.05, n=4) when compared to 
time-matched controls (11.4 ± 0.7 mmHg, n=7 and 1.7 ± 0.7g, n=7 
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Figure 3.19. The effect of Phalloidin (50 nM) on Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) following hypoxic perfusion in 
the isolated ventilated recirculating perfused rat lung. n=4-7, ** p<0.01 
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Figure 3.20. The effect of Colchicine (100nM) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated recirculating perfused rat lung. 
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Figure 3.21. The effect of Cycloheximide (5p,M) on Pulmonary 
Perfusion Pressure (PPP) and Lung Weight (LW) following hypoxic 
perfusion in the isolated ventilated recirculating perfused rat lung. 




Following the above recirculating perfusion experiments where PPP, 
PIP and LW were recorded, the perfusates were collected and stored 
at -80°C for ET-1 determination.
Effects of Hypoxia
Normoxic perfusion (90 min) resulted in an ET-1 level of 0.23 ± 0.03 
pg/ml perfusate (n=9). Following 90 min hypoxic perfusion the ET-1 









Figure 3.22. The effect of Normoxic and Hypoxic recirculating 
perfusion in rat lung on perfusate levels of ET-1. n=8-9, *** p<0.001.
98
EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONISTS ON
ENDOTHELIN-1 LEVELS
(a) BQ123
The endothelin ETa receptor antagonist BQ123 (1.5 pM) significantly 
lowered circulating ET-1 levels when compared to time-matched 
hypoxic controls (0.40 ± 0 . 1 0  pg/ml vs 0.93 ± 0 . 1 0  pg/ml, n=6-8, 
p<0.01; see Figure 3.23).
(b) BQ788
BQ788 (3 jllM), an ETb receptor antagonist, significantly increased ET- 
1 levels to 2.62 ± 0.43 pg/ml (n=6, p<0.01), when compared to hypoxic 
controls (0.93 ± 0.10 pg/ml, n=8; see Figure 3.23).
(c) Bosentan
The mixed ETa/ETb receptor antagonist bosentan (1.5 pM) attenuated 
the hypoxia induced increase in ET-1 from 0.93 ±0 .10 pg/ml to 0.35 ± 
0.9 pg/ml (n=5-8, p<0.01; see Figure 3.23).
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EFFECT OF AN ENDOTHELIN CONVERTING ENZYME INHIBITOR
ON ENDOTHELIN-1 LEVELS
Phosphoramidon
The endothelin converting enzyme inhibitor phosphoramidon (1pM) 
significantly reduced the ET-1 levels when compared to the hypoxic 
control and significantly increased the levels when compared to the 
normoxic control (0.58 ± 0.1 pg/ml vs 0.93 ±0 .10  pg/ml and 0.23 ± 








































Figure 3.23. The effect of BQ123, BQ788, bosentan and 
phosphoramidon on perfusate ET-1 levels following recirculating 
hypoxic perfusion in rat lung. *** p<0.001 vs Normoxic control; + 
p<0.05, ++ p<0.01 vs Hypoxic control; # p<0.05 vs Normoxic control, 
n=3-9.
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EFFECT OF CYTOSKELETAL MODIYFYING AGENTS ON
ENDOTHELIN-1 LEVELS
Phalloidin and Colchicine
The f-actin stabiliser phalloidin (50 nM) and the microtubule disrupting 
agent colchicine (100nM) significantly reduced the circulating ET-1 
levels when compared to hypoxic time-matched controls (0.32 ± 0.07 
pg/ml and 0.20 ± 0.03 pg/ml respectively vs 0.93 ±0.10 pg/ml, n=4-8, 
p<0.01; see Figure 3.24).
EFFECT OF A PEPTIDE SYNTHESIS INHIBITOR ON ENDOTHELIN- 
1 LEVELS
Cvcloheximide
The protein synthesis inhibitor cycloheximide (5jxM) significantly 
reduced the hypoxia induced increase in circulating ET-1 levels form 
0.93 ±0 . 1 0  pg/ml to 0.12 ± 0.04 pg/ml, n=5-8, p<0.001 (see Figure 
3.24).
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Figure 3.24. The effect of Phalloidin, Colchicine and Cycloheximide 
on perfusate ET-1 levels following recirculating hypoxic perfusion in rat 
lung. *** p<0.001 vs Normoxic control; +++ p<0.001, ++ p<0.01 vs 
Hypoxic control, n=4-9.
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TISSUE ENDOTHELIN-1 LEVELS 
Exposure to hypoxia
Following 90 min normoxic recirculating perfusion, tissue levels of ET- 
1 were found to be 141.0 ±11.1 pg/mg protein (n=6). Recirculating 
hypoxic perfusion (90 min) resulted in measured tissue levels of ET-1 
of 148.5 ± 12.9 pg/mg protein (n=5). This was not significantly 































Figure 3.25. The effect Normoxic and Hypoxic recirculating perfusion 
on tissue ET-1 levels in rat lung, n=5-6.
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EFFECTS OF ENDOTHELIN RECEPTOR ANTAGONISTS ON
TISSUE ENDOTHELIN-1 LEVELS
fa) BQ123
The endothelin ETa receptor antagonist BQ123 (10 pM) lowered the 
tissue levels of ET-1 to 113.8 ±  16.0 pg/mg protein (n=4) when 
compared to the hypoxic control (148.5 ± 12.9 pg/mg protein, n=5), 
however this was not significant (see Figure 3.26).
(b) Bosentan
The mixed ETa/ETb receptor antagonist bosentan (1.5 pM) significantly 
lowered the tissue ET-1 level to 73.2 ± 7.9 pg/mg protein (n=5) when 
compared to both the normoxic and hypoxic controls (141.0 ± 11.1 
pg/mg protein, n=6, p<0.05 and 148.5 ± 12.9 pg/mg protein, n=5, 










































Figure 3.26. The effect of BQ123 and Bosentan on tissue ET-1 levels 
following recirculating hypoxic perfusion in rat lung, n=4-6; ## p< 0.01 
vs Normoxic; ** p < 0.01 vs Hypoxic.
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EFFECT OF CYTOSKELETAL MODIYFYING AGENTS ON TISSUE
ENDOTHELIN-1 LEVELS
Phalloidin and Colchicine
Both the f-actin stabiliser phalloidin (50 nM) and the microtubule 
disrupting agent colchicine (100 nM) reduced the hypoxic tissue ET-1 
levels from 148.5 ± 12.9 pg/mg protein to 115.5 ±9.1 and 117.4 ± 17.1 
pg/mg protein (n=4-5). However these differences were not significant 
(see Figure 3.27).
EFFECT OF A PEPTIDE SYNTHESIS INHIBITOR ON TISSUE 
ENDOTHELIN-1 LEVELS
Cvcloheximide
The peptide synthesis inhibitor cycloheximide (5 jiM) significantly 
reduced the tissue ET-1 levels when compared to both the normoxic 
and hypoxic controls (79.0 ± 8.7 pg/mg protein vs 141.0 ± 11.1 and 






















































Figure 3.27. The effect of Phalloidin, Colchicine and Cycloheximide on 
tissue ET-1 levels following recirculating hypoxic perfusion in rat lung, 
n=4-6; # p< 0.05 vs Normoxic; ** p < 0.01 vs Hypoxic.
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TISSUE PREPRO ENDOTHELIN-1 mRNA LEVELS
The results from the PCR amplification of the prepro ET-1 mRNA 
show an increase in tissue levels following 90 min perfusion of single 
pass hypoxia, when observed against time-matched normoxic tissues 
(see Figure 3.28). The results for both the prepro endothelin-1 and rat 
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Figure 3.28. The effect of 90 min single pass hypoxic perfusion on A) 
rat G-actin and B) rat prepro ET-1 mRNA levels in the isolated rat lung. 
L 100bp ladder; 1-4 Normoxic perfusion; 5-8 Hypoxic perfusion; 9 
sterile distilled water control; 10 running buffer control.
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ACTIONS OF ENDOTHEUNS AND SARAFOTOXINS ON THE LUNG
The bolus dose used to illustrate the effects of ETs and Sx6c on the 
measured parameters, was picked in response to its actions on the 
preparation. The dose produces a sub-maximal response which is 
significant when compared to basal parameters.
Endothelin-1
The effects of endothelin-1 (ET-1) on PPP, PIP and LW are illustrated 
in Figure 3.29. It can be seen that ET-1 caused a dose-dependent 
increase in PPP, PIP and LW (50 - 800 pmol). The increase in PPP 
was sustained at low doses (50 - 200 pmol), however, at higher doses 
(400 - 800 pmol) the increase in PPP was bi-phasic in nature, with a 
large, rapid, transient rise, which subsided to give a sustained 
increase. ET-1 (400 pmol) increased PPP by 11.5 ± 0.74 mmHg (n=8).
ET-1 caused a steep and irreversible dose-dependent increase in LW 
(see Figures 3.29 and 3.33), which was associated with the 
appearance of fluid in the tracheal cannula, with a 1.04 ± 0.35 g (n=8) 
increase with a 400pmol dose.
In addition to this, ET-1 also caused a dose-dependent increase in PIP 
(see Figures 3.29 and 3.33) . A 400 pmol bolus dose increased PIP 
by 2.89 ± 0.29 mmHg (n=8).
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Endothelin-3
As can be seen in Figure 3.30 ET-3 caused a dose-dependent 
increase in PPP, which was sustained at low doses (50 - 400 pmol), 
but underwent a slow reversal at higher doses (800 - 1600 pmol). The 
increase in PPP with a 400 pmol bolus dose was 4.25 ± 0.59 mmHg 
(n=6).
ET-3 also caused a dose-dependent increase in PIP, which was 
similar to the responses seen with ET-1 (3.42 ± 0.35 mmHg, n=6; see 
Figures 3.30 and 3.33).
The ET-3 induced increase in LW was irreversible, with a 0.23 ± 0.06 g 
increase with a 400 pmol bolus dose (see Figures 3.30 and 3.33).
Sarafotoxin 6c
Sarafotoxin 6c (Sx6c) induced dose-dependent increases in PPP, 
which slowly reversed at both low (50 -200 pmol) and high doses (400 
- 800 pmol; see Figures 3.31 and 3.33). 400 pmol Sx6c increased 
PPP by 8.17 ± 0.59 mmHg (n=5).
In addition to this, Sx6c increased PIP in a dose-dependent fashion, 
with the lower doses of peptide (50 - 200 pmol), undergoing a slow 
reverse, and higher doses (400 - 800 pmol) causing a sustained 
increase in PIP. The 400 pmol dose of Sx6c caused an increase in 
PIP of 11.5 ± 0.96 mmHg (see Figures 3.31 and 3.33).
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Sx6c also increased LW in a dose-dependent fashion, with 400 pmol 
causing a 5.32 ± 1.56 g increase in LW (see Figures 3.31 and 3.33)
Big Endothelin-1
Big ET-1, the precursor peptide of ET-1, when given as bolus doses to 
the lung caused dose-dependent increases in PPP, PIP and LW (see 
Figure 3.32). The increases in PPP were significantly less than the 
increases observed with equal doses of ET-1 (for example 400 pmol 
big ET-1 increased PPP by 5.58 ± 0.42 mmHg, compared to the ET-1 
response of 11.5 ± 0.74 mmHg (n=6-8, p<0.001). It should be noted 
that an 800 pmol bolus dose of big ET-1 was needed to produce the 
same increase in vascular resistance as that seen following the 
administration of a 200 pmol bolus dose of ET-1.
The increase in PIP observed with big ET-1 was equipotent with ET-1, 
with a 400 pmol bolus dose of big ET-1 inducing a 2.35 ± 0.31 mmHg 
increase in PIP, compared to a 2.89 ± 0.29 mmHg increase for ET-1 
(n=6-8).
The increase in LW following administration of big ET-1 was not as 
great as that seen following the administration of equivalent doses of 
ET-1, with 400 pmol big ET-1 increasing LW by 0.32 ± 0.08 g, 
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Figure 3.29. The effect of Endothelin-1 on Pulmonary Perfusion 
Pressure (PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight 
(LW) in an isolated, ventilated perfused rat lung (representative trace 
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Figure 3.30. The effect of Endothelin-3 on Pulmonary Perfusion 
Pressure (PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight 
(LW) in an isolated, ventilated perfused rat lung (representative trace 
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Figure 3.31. The effect of Sarafotoxin 6c on Pulmonary Perfusion 
Pressure (PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight 
(LW) in an isolated, ventilated perfused rat lung (representative trace 








Figure 3.32. The effect of Big Endothelin-1 on Pulmonary Perfusion 
Pressure (PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight 
(LW) in an isolated, ventilated perfused rat lung (representative trace 
from 6 similar experiments).
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Figure 3.33. The effects of Endothelin-1, Endothelin-3 and 
Sarafotoxin 6c on changes in Pulmonary Inflation Pressure (PIP), 
Pulmonary Perfusion Pressure (PPP) and Lung Weight (LW) in 
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Figure 3.34. The effects of Big Endothelin-1 and Endothelin-1 on 
changes in Pulmonary Inflation Pressure (PIP), Pulmonary Perfusion 
Pressure (PPP) and Lung Weight (LW) in isolated, ventilated perfused 
rat lungs. n=6-8, * p<0.05, ** P<0.01, *** p<0.001 vs Endothelin-1.
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EFFECTS OF ENDOTHELIN RECEPTOR-ANTAGONISTS UPON 
THE ACTIONS OF ENDOTHELINS AND SARAFOTOXIN ON THE 
LUNG
Endothelin-1
The endothelin ETa receptor antagonist BQ123 (3 pM) significantly 
attenuated the ET-1 induced increase in PPP (for example, 400pmol 
ET-1 increased PPP by 11.5 ± 0.74 mmHg, whereas in the presence 
of 3 pM BQ123 the increase in PPP was 2.38 ± 0.38 mmHg, p<0.001, 
n=4-8).
The endothelin E T b  receptor antagonist BQ788 ( 3  pM) had no effect 
on the ET-1 induced vasoconstriction, with 400 pmol ET-1 increasing 
PPP by 10.88 ± 0.80 mmHg (n=4), compared to the control value of 
11.5 ± 0.74 mmHg (n=8).
In combination, the ETa receptor antagonist BQ123 and the ETb 
receptor antagonist BQ788 (both 3 pM) significantly inhibited the ET-1 
induced increase in PPP (1.5 ± 0.20 mmHg vs 11.5 ± 0.74 mmHg for a 
400 pmol bolus dose, n=4-8, p<0.001; see Figures 3.35 + 3.39).
BQ123 (3 pM) had no significant effect upon the ET-1 induced 
increase in PIP, with 400 pmol increasing PIP by 2.38 ± 0.24 in the 
presence of BQ123, against the ET-1 control of 2.89 ± 0.29 mmHg 
(n=4-8).
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The ETb receptor antagonist BQ788 (3 pM) significantly increased the 
ET-1 induced increase in PIP, with 400pmol ET-1 increasing PIP by 
4.75 ± 1.20 mmHg compared to the ET-1 control of 2.89 ± 0.29 mmHg 
(n=4-8, p<0.01).
The combination of BQ123 and BQ788 (both 3 pM) significantly 
inhibited the ET-1 induced increase in PIP from 2.89 ± 0.29 mmHg to 
0.89 ± 0.24 mmHg (n=4-8, p<0.001; see Figure 3.35) for a 400 pmol 
bolus dose.
With regard to the increase in LW observed with ET-1 (1.04 ± 0.35 g 
for a 400 pmol dose, n=8), the ETA receptor antagonist BQ123 (3 pM) 
significantly attenuated the increase seen, with a 400 pmol bolus 
reducing the increase in LW to 0.05 ± 0.03 g (n=4, p<0.05). However 
the ETb receptor antagonist BQ788 had no significant effect (0.45 ± 
0.15 g, n=4, for a 400pmol dose). The combination of BQ123 and 
BQ788 (3 pM) also attenuated the ET-1 induced increase in LW (400 




The addition of ET-3 in the presence of the endothelin ETa selective 
receptor antagonist BQ123 (10 pM) did not alter the rise in PPP 
observed (400 pmol producing an increase of 5.00 ± 0.50 mmHg when 
compared to the ET-3 control of 4.25 ± 0.59 mmHg, n=5-6). The ETb 
receptor antagonist BQ788 (3 pM) significantly lowered the ET-3 
induced increases in PPP, with a 400 pmol bolus dose producing an 
increase in PPP of 1.33 ± 0.44 mmHg when compared to the control 
increase of 4.25 ± 0.59 mmHg (n=5-6, p<0.05).
The maximal ET-3 induced increase in PIP was not affected by the 
addition of 10 pM BQ123, although the curve was displaced to the left, 
this shift was not significant (for example, the 400 pmol bolus dose 
increased PIP by 5.16 ± 0.17 mmHg in the presence of 10 pM BQ123, 
compared to the ET-3 control value of 3.42 ± 0.35 mmHg, n=3-6). The 
ETb receptor antagonist BQ788 significantly attenuated the ET-3 
induced increase in PIP, with the higher doses (400 - 1600 pmol) all 
being significantly reduced (the 400 pmol ET-3 induced increase in 
PIP was reduced from 3.42 ± 0.35 mmHg to 0.50 ± 0.00 mmHg in the 
presence of BQ788, n=3-6, p<0.001, see Figure 3.36).
BQ123 (10 pM) had no effect upon the ET-3 induced increase in LW, 
up to 800 pmol. However, BQ788 (3 pM) did inhibit the increase in LW 
induced by ET-3 at higher doses (800 - 1600 pmol). For example, 800 
pmol ET-3 increased LW by 0.17 ± 0.03 g in the presence of BQ788,
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compared to the ET-3 control value of 2.35 ± 0.63 g (n=3-6, p<0.001, 
see Figures 3.36 + 3.40).
Sarafotoxin 6c
Inclusion of the ETB receptor antagonist BQ788 (3 |xM) inhibited the 
Sx6c induced increase in PPP, PIP and LW. 400 pmol Sx6c, in the 
presence of 3p,M BQ788 produced an increase in PPP of 1.67 ± 0.33 
mmHg, compared with the control Sx6c increase of 11.5 ± 0.96 mmHg 
(n=5-6, p<o0.001). PIP increased by 1.33 ± 0.17 mmHg in the 
presence of 3 pM BQ788, compared to the control of 8.7 ± 0.59 mmHg 
(n=5-6, p<0.001), with a 400 pmol bolus dose of Sx6c. The increase 
in LW in the presence of BQ788 was 0.08 ± 0.05 g, contrasted with the 
5.32 ± 1.65 g increase in the Sx6c control (n=5-6, p<0.001; see 
Figures 3.37 + 3.41).
Big Endothelin-1
The ECE inhibitor phosphoramidon (1 pM) inhibited the big ET-1 
induced increase in PPP, PIP and LW, with a 400 pmol bolus, in the 
presence of phosphoramidon, producing 2.58 ± 0.66 mmHg, 0.7 ± 0.1 
mmHg and 0.03 ± 0.04 g increases in PPP,PIP and LW respectively. 
These contrast with the increases seen with big ET-1 of 5.58 ± 0.42 
mmHg, 2.35 ± 0.31 mmHg and 0.32 ± 0.08 g, respectively (n=6-8, see 
Figures 3.38 + 3.42).
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Figure 3.35. The effects of BQ123 and BQ788 both alone and in 
combination on bolus administration of Endothelin-1 on changes in 
Pulmonary Inflation Pressure (PIP), Pulmonary Perfusion Pressure 
(PPP) and Lung Weight (LW) in isolated, ventilated perfused rat lungs. 
n=4-8, * p<0.05, ** P<0.01, *** p<0.001 vs Endothelin-1.
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Figure 3.36. The effects of BQ123 and BQ788 on bolus
administration of Endothelin-3 on changes in Pulmonary Inflation 
Pressure (PIP), Pulmonary Perfusion Pressure (PPP) and Lung 
Weight (LW) in isolated, ventilated perfused rat lungs. n=3-6, * 

































Figure 3.37. The effect of BQ788 on bolus administration of 
Sarafotoxin 6c on changes in Pulmonary Inflation Pressure (PIP), 
Pulmonary Perfusion Pressure (PPP) and Lung Weight (LW) in 
























- m -  Big ET-1








Figure 3.38. The effect of Phosphoramidon on bolus administration of 
Big Endothelin-1 on changes in Pulmonary Inflation Pressure (PIP), 
Pulmonary Perfusion Pressure (PPP) and Lung Weight (LW) in 
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Figure 3.39. The effect of BQ 123 and BQ788 in combination on 
Pulmonary Perfusion Pressure (PPP), Pulmonary Inflation Pressure 
(PIP) and Lung Weight (LW) following bolus Endothelin-1 
administration in an isolated, ventilated perfused rat lung 
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Figure 3.40. The effect of BQ788 on Pulmonary Perfusion Pressure 
(PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight (LW) 
following bolus Endothelin-3 administration in an isolated, ventilated 
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Figure 3.41. The effect of BQ788 on Pulmonary Perfusion Pressure 
(PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight (LW) 
following bolus Sarafotoxin 6c administration in an isolated, ventilated 
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Figure 3.42. The effect of Phosphoramidon on Pulmonary Perfusion 
Pressure (PPP), Pulmonary Inflation Pressure (PIP) and Lung Weight 
(LW) following bolus Big Endothelin-1 administration in an isolated, 





In this series of experiments, the involvement of endothelins in the 
responses to systemic hypoxia in an isolated perfused rat lung has 
been investigated. The responses to hypoxia could be inhibited by a 
variety of agents which have been shown to inhibit ET formation, 
secretion and action. In addition to this, an increase in perfusate 
levels of ET-1 and an increase in the lung levels of prepro ET-1 mRNA 
had been detected, which indicate that hypoxia stimulates ET-1 
production in this model.
The use of isolated perfused lungs to study aspects of pulmonary 
function is well known. However the criteria for the stability of the 
preparation are varied. It has been demonstrated that lungs perfused 
under normoxic conditions in this model and in this study are stable for 
2 hours, with no increase in PPP, PIP or LW and that the responses to 
agonists (phenylepherine, carbachol, bradykinin and angiotensin-1) 
are reproducible throughout the 2 hour period (Lai, 1995).
The use of a single pass perfusion model allows for removal of 
substances robust enough to withstand passage through the lung, 
which may, in reperfused lungs, continue to act on subsequent 
passages, complicating interpretation of the results. It should be noted 
that the addition of a plasma expander to the perfusate (for example 
dextran, ficoll or albumin), to offset oedema formation in the perfused 
lung, has been widely reported in the literature (Selig et a i, 1988; 
Drazen et al., 1989; Westcott et a i, 1990; Czartolomna et al., 1991;
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Seale et al., 1991; Pino et al., 1992; Bonvallet et al., 1993; Uhlig and 
Wollin, 1994). The omission of a plasma expander in the perfusate 
was a considered choice, due to the expense.
The perfusion rate used in this study (5 ml min'1) has been shown to 
be a rate which allows maximum stability of the preparation with 
minimum oedema formation over the time course of the experiment. 
Increasing the flow rate has been shown to produce a more rapid 
development of oedema (Lai, 1995). In addition to this, Fisher et al., 
(1980) demonstrated that rat lungs perfused with a Krebs’ solution at a 
rate of 12 - 25 ml min'1 showed development of gross alveolar oedema 
after 1 hour.
The low pulmonary inflation rate and inflation volume were used to 
prevent stress damage to the vasculature (West and Mathieu-Costello, 
1992), as even moderate over-inflation has been shown to cause lung 
injury (Cilley et al., 1993). The normal tidal volume for a male Wistar 
rat of the weight used in this study is 1.6 ml, with a respiratory rate of 
90 breaths min'1 (Flecknell, 1995). In this study, we have used a tidal 
volume of 1ml, which although lower than the rat tidal volume, has 
been shown to allow measurement of changes in airway tone in this 
model (Lai et al., 1994). The relatively low inflation rate used was 
chosen to prolong the viability of the preparation.
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In preliminary studies with hypoxic perfusion, it was noted that the use 
of standard silicone laboratory tubing with the isolated lung apparatus 
allowed oxygen diffusion both into and out of the equilibrated Kreb’s 
buffer, dependent upon the gassing regimen used, thus altering the 
PO2 . To combat this, and prevent the PO2 falling under normoxic 
conditions or increasing under hypoxic conditions, all perfusion and 
ventilation tubing was switched to proprietary brands (Tygon and 
PharMed) which report low oxygen permeability. Changing the tubing 
resulted in a reduction in diffusion of oxygen into the Krebs from the 
atmosphere, and allowed greater control and stability of perfusate 
P 02, both under normoxic and hypoxic conditions.
The use of normoxic Krebs gassed with either 95% 0 2 or 20% O2 had 
no effect upon the viability of the preparation. For the remainder of the 
study, normoxic perfusion was performed with the Krebs gassed with 
20% O2 as this was deemed to be of a greater physiological relevance 
than 95% O2 .
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EFFECTS OF HYPOXIA ON THE ISOLATED RAT LUNG
Hypoxic perfusion of the isolated ventilated lung, in a single pass 
manner, resulted in a slow increase in PPP, followed by an increase in 
LW. The increase in PPP is consistent with the phase 2 HPV reported 
by Jin etaL (1992) and Ward and Robertson (1995). The mechanisms 
underlying the sensing of the fall in PO2 and the subsequent 
vasoconstriction seen are not yet completely understood, but data 
presented in this thesis indicates that endogenous endothelin could be 
involved in mediating the responses seen (see later).
The lack of a phase 1 response, in this study, cannot be accounted 
for, although it should be noted that the majority of phase 1 responses 
are seen in pre-constricted pulmonary vessels, or isolated lungs with 
raised vascular tone. Indeed, it has been reported that the magnitude 
of HPV seen in isolated rings is proportional to the level of pre­
stimulation of the vessels with any given agonist, and the severity of 
the hypoxia (Rodman et al., 1989). The fact that an exogenous 
constrictor agent was not used in this study could explain the lack of a 
phase 1 response.
In addition to the single pass perfusion system, a recirculating method 
was developed. This was used to investigate the release of ET(s) from 
the lung in response to hypoxia. To accomplish this, the same 
perfusion parameters as for single pass perfusion were used, with the
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perfusate volume reduced to 50 ml, which was gassed with the 
appropriate humidified gas and recirculated.
Following hypoxic perfusion in the recirculating system, the PPP and 
LW increased, but not to the same degree as in the single pass 
system (see Figures 3.2 and 3.14). This discrepancy could be due to 
the release of endogenous vasodilator substances that have a 
persistent action in recirculating Kreb’s perfusate (Chang and Voelkel, 
1992). As with the single pass system, no significant change in PIP 
was observed.
The ai-selective antagonist prazosin, at a concentration which has 
been shown to inhibit the phenylepherine induced increase in PPP 
(Lai, 1995), had no effect on the responses to single pass hypoxia in 
the model, indicating that activation of ai adrenoceptors played no role 
in the development of HPV. This is in agreement with the findings of 
Fishman (1976) and McLean (1986).
The cyclo-oxygenase inhibitor indomethacin, which at the 
concentration used, effectively inhibits the production of prostacyclin 
and thromboxane A2 in isolated perfused rat lungs (Chang and 
Voelkel, 1992) inhibited HPV, but not the associated increase in LW. 
This is in contrast to reports indicating that inhibition of cyclo-
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oxygenase enhances HPV, presumably through inhibition of 
endogenous vasodilator prostanoids (Haynes et al., 1988; Ward and 
Robertson, 1995). The lack of effect of indomethacin on the increase 
in LW in the present study would indicate that prostanoids are not 
involved in mediating the LW changes, and that the increase in LW is 
as a result of something other than a hydrostatic oedema secondary to 
a vascular constriction.
It has been shown that although hypoxia reduces NO production in 
proximal pulmonary arteries, production is enhanced in the small 
arteries (Kovitz et al., 1993). Another report suggested that although 
NO may be important in the regulation of vascular tone and may have 
a modulatory role in hypoxia, it is unlikely to be a major factor in the 
development of HPV (Ward and Robertson, 1995).
To investigate the possibility that a decrease in NO could be the cause 
of the increase in vascular resistance following hypoxia, NO synthesis 
was inhibited prior to hypoxia with the NOS inhibitors nitro-L-arginine 
and nitro-L-arginine methyl ester (L-NAME). These agents were used 
at concentrations that have been demonstrated to block both the 
constitutive and inducible form of NOS (Griffith and Kilboum, 1996). 
The NOS inhibitors had no effect on the basal vascular resistance, and 
had no effect on the hypoxia-induced increase in vascular resistance, 
which is in agreement with previously published data (Jin et al., 1992;
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Leach et al., 1994), and suggests that in this model a decrease in the 
release of the vasodilator NO is not the cause of the HPV. However 
these results contrast with the results of Ogata et al. (1992), who 
showed that N(G)-monomethyl-L-arginine enhanced the hypoxia 
induced vasoconstriction in isolated pulmonary artery rings. In 
addition, Sprague et al. (1992) have demonstrated that L-NAME 
produced dose dependent decreases in blood flow to the nitrogen 
ventilated lung in an animal model of unilateral alveolar hypoxia.
It should be noted that L-NAME prevented the increase in LW caused 
by hypoxia in this model. The lack of effect of nitro-L-arginine with 
regard to the induced increases in LW cannot be explained, as L- 
NAME is metabolised to nitro-L-arginine within the cell, and thus the 
active inhibitor is the same (Griffith and Kilboum, 1996). This suggests 
that L-NAME may have some actions independent of NOS inhibition.
The NOS substrate L-arginine, in the absence of nitro-L-arginine and 
L-NAME, inhibited the HPV, possibly through increasing the production 
of the dilator substance NO. The lack of effect of L-arginine on the 
hypoxia-induced increase in LW provides further evidence for the 
independent nature of changes in vascular resistance and lung weight 
in this model. Together, these results show that there is no evidence 
for NO involvement in the development of HPV in this model.
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Following the development of an isolated perfused rat lung model that 
responded to systemic hypoxia, and evidence in the literature that 
endothelins were released in response to hypoxia in several species 
(Perreault et al., 1990; Rakugi et al., 1990; Horio et al., 1991; 
Shirakami et al., 1991), the role of endothelins in the responses to 
hypoxia was investigated. This was accomplished by using the 
endothelin E T a  receptor antagonist BQ123 (lhara et al., 1992), the 
endothelin E T b  receptor antagonist BQ788 (Ishikawa et al., 1994) and 
the mixed endothelin E T a / E T b  receptor antagonist bosentan (Clozel et 
al., 1994).
BQ123, an E T a  receptor antagonist (lhara et al., 1992), inhibited the 
increase in vascular resistance, and the increase in LW in a 
concentration dependent fashion in the single pass system. In the 
recirculating system BQ123 also blocked both the increase in PPP and 
LW, indicating a role for E T a  receptors in the responses observed. 
This is in agreement with results published showing that BQ123 can 
prevent the development of pulmonary hypertension following 
exposure to chronic hypoxia (Bonvallet et al., 1993; Chen et al., 1993; 
DiCarlo et al., 1994; Oparil et al., 1995). However it should be noted 
that the above studies were performed in vivo, with exposure to 
hypoxia over a long period of time. The results from the current study 
suggest that endothelin involvement in the responses to hypoxia can 
be demonstrated over a much shorter time scale (90 min). In contrast 
to this Takeoka et al. (1995) demonstrated that BQ123 had no effect
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upon HPV in an isolated rat lung, however the study involved the 
investigation of a 5 min exposure to hypoxia, which is consistent with 
the phase 1 response seen in acute alveolar hypoxia. It is thought that 
the initial phase 1 HPV is due to depolarisation of the cell via closure 
of an oxygen-sensitive potassium channel (Osipenko eta!., 1995; Weir 
and Archer, 1995; Osipenko et al., 1997), and as stated earlier, this 
acute response was not observed when hypoxia was induced 
systemically.
The endothelin E T b  receptor antagonist BQ788 (Ishikawa et al., 1994) 
also attenuated the HPV and increase in LW, both in the single pass 
and recirculating systems. This is in contrast to the findings of Okada 
et al. (1995), who demonstrated that E T b  receptor blockade with RES- 
701-1 increased pulmonary artery pressure in pulmonary hypertension. 
However, recent studies by Lai et al. (1996) and Muramatsu et al. 
(1997) have demonstrated the presence of both E T a  and E T b  
receptors in the lung, and that these receptors contribute to the ET 
induced vasoconstriction. BQ788 has also been shown to inhibit ET-1 
induced vasoconstriction in human isolated pulmonary vessels 
(McCulloch et al., 1996). It is possible that the ETb2 receptor subtype, 
which has been demonstrated to mediate vasoconstriction, is involved 
in the responses seen to hypoxia in this model.
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The mixed E T a / E T b  receptor antagonist bosentan (Clozel et al., 1994) 
blocked the increases in LW, caused by hypoxia, in a concentration 
dependent manner, however the blockade of HPV only occurred at the 
lower concentration (1.5 pM). In the recirculating system, bosentan, at 
the concentration used (1.5 pM), also inhibited the hypoxia-induced 
increases in PPP and LW. This blockade of HPV is in agreement with 
the work of Chen et al. (1994), Chen et al. (1995), Eddahibi et al. 
(1995) and Willett et al. (1997) who have shown that mixed E T a / E T b  
receptor antagonists can prevent and reverse the development of 
pulmonary hypertension in several models, both in vitro and in vivo.
The lack of a concentration-related effect of bosentan on blocking the 
increase in vascular resistance cannot be explained, although Xia and 
Nye (1995) have shown that the related compound Ro46-2005, which 
has a similar structure to bosentan, displays non concentration- 
dependent effects in rat resistance pulmonary artery rings. It may be 
that bosentan is acting as a partial-agonist in the isolated lung.
Therefore, this data presents evidence that ET(s) are involved in the 
responses to hypoxia in this model. To investigate if the ET(s) are 
derived from increased synthesis or release from storage vesicles, an 
ECE inhibitor and agents that interfere with release and synthesis 
were utilised.
The role of big endothelin(s) was investigated by using the endothelin 
converting enzyme inhibitor phosphoramidon (Fukuroda et al., 1990; 
Matsumura et al., 1990; McMahon et al., 1991; Sawamura et al., 
1991). The results indicated that the production of endothelin from big 
endothelin is involved in the responses seen, as the converting 
enzyme inhibitor, phosphoramidon, attenuated both the increase in 
vascular resistance and the increase in lung weight following exposure 
to hypoxia, both in the single pass and recirculating systems. This is in 
agreement with the work of Stadnicka et al. (1995) who showed that 
phosphoramidon could reduce the extent of hypoxic constriction in 
rabbit mesenteric vessels. Vemulapalli et al. (1992) have 
demonstrated that phosphoramidon can abolish the increase in ET-1 
release following ischaemia in the isolated perfused guinea-pig lung. 
However it was later shown that phosphoramidon did not inhibit 
endogenous ET-1 release following hypoxia in the rat, when plasma 
levels were measured (Vemulapalli et al., 1994), however the source 
of the ET-1 could not be identified. The location of the conversion of 
the big ET(s) to the mature peptide(s) is not known, however it has 
been demonstrated that phosphoramidon can enter cells, and it will 
prevent both the intracellular and the extracellular conversion of the 
big ET(s) (Sawamura et al., 1991). The subtype of the ECE involved 
in the conversion of big ET to the mature peptide cannot be identified, 
as phosphoramidon has been shown to inhibit both the ECE-1 and the 
ECE-2 isoforms (Xue etal., 1994; Emoto and Yanagisawa, 1995).
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It is interesting to note the lack of an increase in PIP following 
exposure to hypoxia. If ETs are involved in the responses observed 
following the onset of hypoxia, then it would be expected that PIP 
would increase, as endothelins have been shown to increase airway 
resistance following bolus administration via the pulmonary artery (Lai 
et a!., 1995). However, the effect of hypoxia on airway resistance has 
not been reported in the literature. The lack of an increase in PIP may 
be due to the type of the hypoxia (systemic as opposed to alveolar), 
and if ET(s) are being released from the endothelium, the release 
would probably be polar in nature, and directed towards the vascular 
smooth muscle cells (Yoshimoto et al., 1991; Wagner etal., 1992).
Following the observation that the ETA receptor antagonist BQ123, at 
the lower concentration used (3 pM), inhibited the hypoxia-induced 
increase in PPP, but had no significant effect upon the hypoxia- 
induced increase in LW, and the higher concentration of BQ123 used 
(10 pM) inhibited both the increase in PPP and the increase in LW 
following hypoxia, the possibility of different mechanisms for increases 
in both PPP and LW was raised. To investigate this possibility further, 
the F-actin stabilising agent phalloidin (Estes et al., 1981) was used, 
as it had been demonstrated by Kuroes et al. (1993) that phalloidin 
could inhibit the ET-3 induced increase in vascular permeability in 
superfused rat mesentery, without inhibiting the observed ET-3 
induced vasoconstriction. However, it was found that phalloidin
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attenuated both the increase in PPP and LW following exposure to 
hypoxia both under single pass and recirculating conditions. It has 
been reported by Tasaka and Kitazumi (1994) that F-actin plays a role 
in the secretion of ET-1 from endothelial cells. As a result, the 
phalloidin could well be preventing the release of ET(s) from the 
endothelium, and therefore the inhibition of the hypoxia-induced 
increase in PPP and LW observed following hypoxia may due to the 
inhibition of ET secretion within the lung.
To investigate the involvement of the cytoskeleton in the responses to 
hypoxia further, colchicine, an agent which disrupts microtubules 
(Borisy and Taylor, 1967), which have been reported to be involved in 
the secretion of ET-1 (Kitazumi et a l, 1991), was utilised, again under 
both the single pass and recirculating protocols. The increases in PPP 
and LW were inhibited by colchicine following hypoxic exposure, 
indicating that ET release from the cells within the lung involves the 
microtubules.
Initial reports indicated that there were no storage sites within cells for 
ET-1 (Nakamura, et al, 1990), although endothelial cells may posses 
some preformed ET-1 that stimuli, such as stretch, can release 
immediately (Harrison et a l, 1993; Macarthur et a l, 1994; Harrison et 
al, 1995). To investigate the nature of the source of the ET involved 
in responses to hypoxia in this model (i.e. release from pre-formed
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stores or de novo synthesis), the peptide synthesis inhibitor 
cycloheximide was used (Obrig et al., 1971). If the responses to 
hypoxia are as a result of release of pre-formed ET(s), then pre­
treatment of the lung with cycloheximide would have no effect. If, 
however, the ET release was as a result of de novo synthesis, then 
pre-treatment with cycloheximide would be expected to prevent the 
hypoxia-induced increase in LW and PPP. This is indeed was what 
was observed when cycloheximide was given prior to hypoxia, both 
under the single pass and recirculating systems, indicating that ET 
release is as a result of de novo synthesis.
To investigate the mechanisms involved in the hypoxia-induced 
increase in LW, an albumin bound Evans Blue dye infusion was used 
to investigate changes in vascular permeability. Increased albumin 
bound Evans Blue dye accumulation within the tissue is indicative of a 
permeability change within the lung vasculature (Lai et al., 1995). In 
the present study, it has been shown that the increases in LW 
produced by exposure to hypoxia are associated with a large 
accumulation of albumin bound dye. This suggests that the increase 
in LW following exposure to hypoxia is as a result of a permeability 




Effective concentrations of agents shown to attenuate both HPV and 
the associated increase in LW were also used in the recirculating 
system, and the perfusate samples collected for ET extraction. 
Extraction efficiency of the Amprep ethyl C2 columns has been 
demonstrated to be 75% (A. White, personnel communication).
The levels of ET-1 in the tissues exposed to hypoxia had increased by 
approximately four fold when compared to time-matched normoxic 
controls. Increased ET-1 secretion, in response to hypoxia, has also 
been seen in human umbilical vein endothelial cells (HUVECS; 
Kourembanas et al., 1991; Gertler and Ocasio, 1993; Kourembanas, 
et al., 1993), bovine coronary artery endothelial cells (Hieda and 
Gomez-Sanchez, 1990), human proximal tubular cells (Ong et al.,
1995) and cardiomyocytes (Kagamu et al., 1992). It has been shown 
that in pulmonary artery endothelial cells hypoxia can increase (Golden 
et al., 1995), have no effect on (Hassoun et al., 1995) or decrease 
(Wiebke et al., 1992; Markewitz et al., 1995) ET-1 secretion. Plasma 
ET-1 levels are also increased in animals and humans exposed to 
alveolar hypoxia for more than one hour (Horio et al., 1991; Shirakami 
et al., 1991; Elton et al., 1992; Perella et al., 1992; Li et al., 1994a; 
DiCarrlo etal., 1995; Goerre etal., 1995; Oparil etal., 1995).
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It has been demonstrated that in animals exposed to alveolar hypoxia 
and humans exposed to high altitude the increase in plasma ET-1 
correlates with the decrease in PO2 (Horio et a i, 1991; Shirakami et 
al., 1991; Goerre etal., 1995).
It should be noted that back calculation of the level of ET-1 measured 
in the perfusate falls within the range administered as bolus doses in 
experiments in this study. Assuming a polar secretion for ET-1 from 
endothelial cells, the amount of ET-1 in the perfusate equates to a 
circulating concentration of approximately 5 nM following 90 min 
hypoxia, which equates to a bolus administration of 200 - 400 pmol, 
indicating that the amount of ET-1 released is in the range to cause 
the vasoconstriction and increase in lung weight observed following 
hypoxic exposure.
The endothelin receptor antagonist BQ123 lowered perfusate levels of 
ET-1 following the onset of hypoxia. This is a surprising result, as the 
ET-1 level would be expected to increase following E T a  receptor 
blockade due to ET-1 displacement from the receptors. The reported 
IC5 0 , obtained from ligand binding assays, using radiolabelled ligand, 
for ET-1 and BQ123 on cloned human ETA receptors is reported to be 
0.21 and 13 nM respectively (Dr. T. Brown, Rhone-Poulenc Rorer, 
personal communication). However, it has been reported that hypoxia 
increases both ETA and E T b  receptor mRNA levels in the lung, and
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this may lead to an increase in expression of the receptors (Li et al., 
1994b), however this was measured following chronic hypoxic 
exposure over a period of 4 weeks. Thus, treatment with the E T a  
receptor antagonist BQ123 (lhara et al., 1992) may prevent ET-1 
binding to the E T a  receptor and increase clearance via the E T b  
receptor (Fukuroda et al., 1995; Sato et al., 1995), leading to a 
reduction in the amount of ET-1 seen in the perfusate. The reported 
IC50 value for ET-1  on a cloned human E T b  receptor is 0.1 nM (Dr. T. 
Brown, personal communication), indicating that the E T b  receptor has 
a greater affinity for ET-1  over the ETA receptor. Support for this 
comes from the experiments using the E T b  receptor antagonist 
BQ788.
The E T b  receptor antagonist BQ788 (Ishikawa et al., 1994) increased 
the perfusate ET-1 levels following hypoxia. This is in agreement with 
the findings of Fukuroda et al. (1994) and Sato et al. (1995) who 
showed that the E T b  receptor subtype was responsible for the removal 
of ET-1  from the circulation within the rat lung. Blockade of the E T b  
receptor would prevent removal of the circulating ET-1, and increase 
the perfusate level.
However, the mixed E T a / E T b  receptor antagonist bosentan (Clozel et 
al., 1994) lowered perfusate ET-1 levels. This contrasts with the
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results seen with BQ123 and BQ788, where E T a  receptor blockade 
resulted in a decrease in the perfusate level of ET-1, and E T b  receptor 
blockade resulted in an increase in the perfusate level of ET-1. It 
would be expected that combined E T a / E T b  receptor blockade would 
increase ET-1 levels in the recirculating perfusate, due to blocking the 
E T b  mediated clearance and displacing bound ET-1 from the E T a  
receptors. This theory is in agreement with the results reported by 
Hemsen et al. (1996), who showed that bosentan blocked the 
clearance of ET-1 from the circulation in the pig. Furthermore, Kiowski 
et al. (1995) demonstrated that bosentan doubled the plasma 
concentration of ET-1 in humans. The reason for this discrepancy is 
not clear, however it may be that bosentan may be interfering with the 
ECE, and altering the conversion of big ET to the mature peptide.
The decrease in perfusate ET-1 levels in the presence of the 
endothelin converting enzyme inhibitor phosphoramidon (Fukuroda et 
al., 1990; Matsumura e ta l, 1990; McMahon etal., 1991; Sawamura et 
al., 1991) is probably due to the inhibition of the conversion of big ET- 
1 into the mature peptide ET-1. Evidently phosphoramidon 
suppresses the secretion of ET-1 from endothelial cells via its direct 
inhibitory effect on endothelin converting enzyme (Ikegawa et al., 
1990; Budzik etal., 1991; Sawamura etal., 1991; Sheilds etal., 1991). 
It has also been reported that the C-terminal fragment of big ET-1 is
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also decreased by phosphoramidon, while an increased secretion of 
big ET-1 takes place (Tasaka and Kitazumi, 1994).
Secretion of ET-1 from cells has been reported to involve various 
components of the cytoskeleton (see Figure 4.1; Tasaka and Kitazumi, 
1994). It has been reported that thrombin, a secretagogue of ET-1, 
increases polymerised tubulin content of cells without affecting the 
total tubulin content (Kitazumi et al., 1991). From these findings, it is 
suggested that the microtubular system may play an important role in 
the secretion of ET-1. This is in agreement with the results seen in 
this study, where the microtubule disrupting agent colchicine (Borisy 
and Taylor, 1967) lowered the ET-1 release in response to hypoxia. In 
addition to this, the involvement of the actin/myosin system has been 
reported (see Figure 4.1; Kitazumi and Tasaka, 1992). This can be 
examined by using the F-actin stabilising agent, phalloidin (Estes et al., 
1981). The F-actin stabilising agent phalloidin inhibited the ET-1 
secretion in response to hypoxia in this model, in agreement with the 
findings of Kitazumi and Tasaka (1992).
Together, these results indicate that ET-1 secretion from the lung 































PPET-1 gene PPET-1 mRNA
Figure 4.1. Process leading to secretion of ET-1 from endothelial 
cells. R, receptor; G, G-protein; PLC; phospholipase C; PI, 
phosphotidylinositol; PIP, phosphotidylinositol 4-monophosphate; PIP2, 
phosphotidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5-triphosphate; 
DG, SA7-1,2-diacylglycerol; ER, endoplasmic reticulum; RER, Rough 
endoplasmic reticulum; MLCK, myosin light chain kinase; MLC, myosin 
light chain (reproduced from Tasaka and Kitazumi, 1994).
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If ET-1 is produced as a result of de novo synthesis in response to 
hypoxia, then inhibition of peptide synthesis would result in a reduction 
of ET-1 production. This hypothesis was tested by utilising the peptide 
synthesis inhibitor cycloheximide (Obrig et al., 1971) which inhibited 
the hypoxia-induced increase in perfusate ET-1 levels. This is in 
agreement with the results of Bodi etal. (1995) who reported that ET-1 
release stimulated by hypoxia from early passage endothelial cells 
could be inhibited by cycloheximide.
TISSUE ENDOTHELIN-1 LEVELS
After recirculating hypoxic perfusion, lungs were snap frozen, and ETs 
extracted. When compared with tissues exposed to normoxic 
perfusion, hypoxia had no significant effect upon the tissue levels of 
ET-1. Similar findings have been reported by Ono et al., (1992) and 
Stelzner etal. (1992) who found no increase in whole lung ET-1 levels 
in response to hypoxia in the rat. This contrasts with the reports of 
Shirakami etal. (1991) and Li etal. (1994a) who observed an increase 
in the whole lung ET-1, following 48 hour exposure to 10% O2 . The 
lack of an increase in whole lung ET-1 levels can be explained, if ET-1 
is produced and secreted in response to stimuli; then lung 
homogenate levels would expect to remain constant (providing 
translocation of ET-1 out of the cell is not rate limiting), as there is no 
evidence for storage vesicles within the cells, and synthesised ET-1
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would be secreted following production. In addition to this, whole lung 
homogenates would contain not only cellular ET-1, but also ET-1 
bound to receptors, which may be liberated by the extraction 
procedure and hence interfere with ET-1 measurement. It has been 
reported that the E T b  receptor is responsible for clearing ET-1 from the 
circulation in the rat (Fukuroda e a/., 1994; Sato et a/., 1995). In 
addition to this, following ET binding to the E T a  receptor, the whole 
receptor/ligand complex is internalised (Chun et al., 1995). The 
extraction procedure used may liberate mature ET-1 from big ET-1, 
complicating the measurement of cellular ET-1 even further.
The lowering of the tissue endothelin levels with the E T a  receptor 
antagonist BQ123, as seen in this study, could be due to inhibition of 
ET-1 binding to the E T a  receptor subtype. If binding of ET to the 
receptor is impaired by the receptor antagonist, then total ET-1 in, or 
attached to, a cell would be reduced, and hence the total lung ET 
would be reduced, as more ET would be washed out of the lung in the 
perfusate. However this contrasts with the results reported in this 
study where BQ123 lowers perfusate ET-1 levels. The reason for this 
is not clear.
The reduction in tissue levels of ET-1 following bosentan treatment 
may be due to the occupancy of ETA and E T b  receptors by the
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antagonist, displacing bound ET into the perfusate and increasing 
removal from the tissue (Clozel et al., 1994) Therefore, receptor 
blockade may reduce cellular levels of ET-1, which would be seen as a 
reduction in whole tissue levels. However in this study, bosentan 
lowers the perfusate ET-1 levels.
The disruption of the cytoskeletal components F-actin and tubulin by 
phalloidin (Estes etal., 1981) and colchicine (Borisy and Taylor, 1967) 
would be expected to increase tissue endothelin-1 levels, as inhibition 
of secretion of the peptide would lead to increased accumulation within 
the tissue. However, if endothelins are not being secreted and 
consequently not removed from the circulation, then the tissue levels 
may not change, as any ET secreted is probably going to be taken up 
into the endothelium via internalisation after combination with its 
receptor. This may explain the lack of any significant effect of these 
agents upon the tissue levels of ET-1.
If ET-1 is produced as a result of de novo synthesis following hypoxia, 
as has been suggested by Tasaka and Kitazumi (1994), then inhibition 
of peptide synthesis by cycloheximide (Obrig et al., 1971) should lead 
to a reduction of whole tissue ET-1 levels. The results obtained 
showed a reduction in tissue ET-1 levels, in agreement with the results 
of Bodi etal. (1995).
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Increased prepro endothelin-1 mRNA levels following exposure to 
hypoxia have been found in the lungs of animals in a number of 
different studies, including those by Shirakakmi et al. (1991), Elton et 
al. (1992), Donahue et al. (1994), Li et al. (1994a), Li et al. (1994b), 
Oparil et al. (1995) and Yang et al. (1997). The increase in prepro 
endothelin-1 mRNA in the lungs is a relatively selective response to 
alveolar hypoxia, as it has been shown that the only other organ it 
occurs, in animals exposed to chronic hypoxia, is the heart (Elton et 
al., 1992; Li et al., 1994a). However, in marked contrast, Ono et al. 
(1992) and Stelzner et al. (1992) have reported that in rats exposed to 
hypoxia for three weeks there was no increase in prepro endothelin-1 
mRNA levels in these animals. It has recently been reported that long 
term exposure to hypoxia leads to a reduction in the initial increase in 
mRNA levels, and this may account for the observation that prepro ET- 
1 mRNA levels showed no increase following three weeks exposure to 
hypoxia (Dr. J.C. Wanstall, personnel communication).
The results from the current study indicate that the increase in 
perfusate ET-1 could well be due to increased. peptide synthesis 
following up-regulation of the endothelin gene in the lung.
Taken together, the results from the single pass studies, recirculating 
studies; and both the perfusate and tissue ET-1 levels and the prepro
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endothelin-1 mRNA levels indicate that endothelins play an important 
role in the responses to hypoxia seen in this model.
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ENDOTHELINS IN THE LUNG
Following the demonstration of ET-1 involvement in the responses to 
hypoxia in this model, the receptor subtypes involved in the responses 
to ETs were investigated. ET-1, ET-3 and Sx6c produced dose- 
dependent increases in PPP, PIP and LW following bolus 
administration. These findings are in agreement with the responses 
reported in other rat lung preparations (Rodman et al., 1992; Bonvallet 
etal., 1993; Hisaki, et al., 1994a; Hisaki etal., 1994b; Lai etal., 1995) 
and the responses seen in isolated pulmonary vessels in the rat 
(Wanstall and O’Donnell, 1990; Rodman et al., 1992; Bonvallet et al., 
1993; Hisaki etal., 1994a; Hisaki etal., 1994b).
The finding in this study that, at low doses, ET-1 is more potent than 
ET-3 at causing vasoconstriction indicates that this response is partly 
mediated by an ETA receptor subtype (Webb, 1991). This is 
supported by the observation that BQ123, an ETA specific receptor 
antagonist (lhara et al., 1992), caused an inhibition of the ET-1 
constrictor response (Bonvallet et al., 1993; Sogabe et al., 1993). 
However the involvement of E T b  mediated constriction cannot be ruled 
out, as BQ123 did not cause a complete inhibition of the ET-1 induced 
vasoconstriction, this was achieved by using a combination of BQ123 
and the specific E T b  receptor antagonist BQ788 (Ishikawa et al.,
1994).
159
BQ123 did not inhibit the ET-3 induced increase in vascular 
resistance, again providing evidence that the response is mediated by 
a combination of E T a  and E T b  receptor subtypes. The ET-3 induced 
increase in vascular resistance was inhibited by the E T b  selective 
antagonist BQ788, indicating that ET-3 is causing vasoconstriction as 
a result of E T b  activation.
The ETb selective agonist Sx6c (Kloog and Sokolovsky, 1989) also 
caused vasoconstriction in the lung. Similar findings have been 
reported in the guinea-pig lung (Noguchi et al., 1993) and in isolated 
rat pulmonary artery rings (MacLean et al., 1994), in addition to the 
isolated rat lung (Lai, 1995).
The precursor peptide of ET-1, big ET-1, also caused vasoconstriction 
in this model, although with reduced potency (approximately four fold 
less potent than ET-1, see Figure 3.34), when compared to ET-1. It 
has been shown that the biological activity of big ET-1 is due to its 
conversion to ET-1 (McMahon et al., 1991; Lehoux et al., 1992; Hisaki 
et al., 1994b). In this model, the endothelin converting enzyme 
inhibitor phosphoramidon inhibited the vasoconstriction caused by big 
ET-1, indicating the presence of a phosphoramidon sensitive ECE 
within the lung.
The bronchoconstrictor potency profile of the ETs (ET-1=ET-3) and the 
results from Sx6c experiments suggest that the E T b  receptor is
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mediating the bronchoconstrictor response seen in this model. Hay et 
al. (1993) have shown that ETs induce contractions via the E T b  
receptor in guinea-pig lung parenchymal strips. This response is 
probably mediated by the ETB2 receptors located on the bronchial 
smooth muscle cells. In addition to this, the E T a  receptor antagonist 
FR139317 has no effect on ET-1 induced contraction of guinea-pig 
trachea (Cardell et al., 1993), which provides further evidence that 
bronchoconstriction is mediated by ETB receptors.
It is interesting to note that the ETB receptor antagonist BQ788 
increased the bronchoconstrictor response to ET-1 in the airways. This 
is in contrast to the majority of results reported, where BQ788 inhibits 
ET-1 induced bronchoconstriction (Battistini et al., 1994; Adner et al., 
1996; Nagase et al., 1997; Takahashi et al., 1997). This may be due 
to the increased amount of ET-1 available for binding to constrictor 
ETa receptors, following inhibition of the ETB receptors by BQ788. It 
has previously been shown that ETa receptors are present within the 
lung (Henry, 1993). Alternatively, BQ788 may block a receptor- 
mediated release of a dilator substance, for example NO (Lai et al.,
1996).
The increase in airway resistance following ET-3 administration was 
not affected by BQ123 (lhara et al., 1992), but completely inhibited by 
the ETb receptor antagonist BQ788 (Ishikawa et al., 1994), indicating 
that the response is mediated by ETB receptors. This is in agreement
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with the observation that the Sx6c induced bronchoconstriction is 
inhibited by the E T b  receptor antagonist BQ788 (Ishikawa etal., 1994).
The bronchoconstriction induced by big ET-1 was equal in magnitude 
to that observed with ET-1, which is in contrast to the responses seen 
in the vasculature, where ET-1 was more potent that big ET-1. This is 
in agreement with the findings of Held et al. (1997), who reported that 
the big ET-1 induced bronchoconstriction was more prominent than 
the vasoconstriction in the isolated perfused rat lung. The reasons for 
the increased activity of big ET-1 compared with ET-1 in the bronchial 
circulation are not clear, although it may be due to the presence of an 
ECE isoform with a greater affinity for big ET-1, or a higher level of the 
enzyme in the bronchial circulation. Phosphoramidon, an endothelin 
converting enzyme inhibitor (Fukuroda et al., 1990; Matsumura et al., 
1990; McMahon etal., 1991; Sawamura etal., 1991) also inhibited the 
big ET-1 induced bronchoconstriction, although at much lower 
concentrations than reported by Held etal. (1997).
Results from the current study indicate that ETs are potent compounds 
in producing increases in lung weight, which supports the findings of 
Pons etal. (1991); Rodman etal. (1992) and Ercan et al., (1993). The 
results from this study and those of Lai (1995) suggests that the 
changes in LW may be due to a direct effect of endothelins on 
vascular permeability, and not just as a result of a hydrostatic oedema 
following venoconstriction (Lai et al. 1996), which is a known result of
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ET action (Horgan et al., 1991; Rodman et al., 1992). It may be that 
endothelin-induced mediator release is responsible for the increase in 
lung weight, as the thromboxane A2 synthesis inhibitor UK 38485 has 
been shown to attenuate ET-1 induced increases in lung weight in an 
isolated perfused rat lung (Ercan et al., 1993). However this is in 
contrast to the results seen in this study, where indomethacin, which 
would also decrease thromboxane production, had no effect upon the 
hypoxia induced increase in LW.
The E T a  and E T b  receptor antagonists BQ123 (lhara et al., 1992) and 
BQ788 (Ishikawa et al., 1994) both attenuated the ET-1 induced 
increase in LW, however, both agents in combination were needed to 
abolish the response in this study. This indicates that both E T a  and 
E T b  receptors are involved in the endothelin-induced increase in LW, 
seen in both single pass and recirculating hypoxic perfusion in this 
model.
The ET-3-induced increases in LW were not altered in the presence of 
BQ123, but completely abolished by the E T b  receptor antagonist 
BQ788. This indicates that with regard to ET-3-induced increases in 
LW, this is probably mediated by the E T b  receptor, although the 
majority of E T b  receptors in the pulmonary vasculature have been 
found to be on the arterial side of the pulmonary circulation (Lai et al.,
1995), and as a result, any increase in LW would not be as a result of 
a hydrostatic oedema, but some other mechanism. The involvement
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of non-ETA receptor mediating changes in permeability, is supported 
by the findings of Kurose et al. (1993), who showed that ET-3-induced 
increases in permeability in the rat mesentery were not affected by the 
E T a  receptor antagonist BQ123. This would indicate that the increase 
in lung weight, in the isolated lung model, is due, at least in part, to a 
permeability change within the vasculature. However the exact 
mechanism responsible for the increase in lung weight remains 
unidentified. The big ET-1 induced increases in lung weight were 
attenuated by the endothelin converting enzyme inhibitor 
phosphoramidon, indicating that conversion of big ET-1 to ET-1 is 
necessary for these effects.
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In summary, the experiments conducted have demonstrated the 
effects of a systemic hypoxia upon an isolated rat lung model, which 
responds with an increase in PPP and LW. This is a similar response 
to that seen in isolated lungs exposed to alveolar hypoxia, where the 
ultimate effect of hypoxia is a fall in the oxygen level within the 
pulmonary circulation.
The involvement of ETs has been demonstrated by the inhibition of the 
development of HPV and its associated increase in LW by the E T a  
receptor antagonist BQ123, the E T b  receptor antagonist BQ788 and 
the mixed E T a / E T b  receptor antagonist bosentan, which indicates the 
involvement of both the E T a  and the E T b  receptor in these responses. 
Furthermore, the endothelin converting enzyme inhibitor 
phosphoramidon, and agents which disrupted the function of the 
cytoskeleton and prevented secretion (colchicine and phalloidin) and 
inhibited peptide synthesis (cycloheximide) also prevented the 
increases in PPP and LW induced by hypoxia.
Exposure to hypoxia in a recirculating system results in an elevation of 
perfusate ET-1 levels, showing that ET-1 is released in response to 
hypoxia in the rat lung. However, tissue ET-1 levels do not alter 
significantly. The use of a peptide synthesis inhibitor (cycloheximide) 
and agents which disrupt the cytoskeleton and prevent secretion 
(colchicine and phalloidin) which prevent the increase in perfusate ET- 
1 levels indicates that the increase in ET-1 observed is as a result of
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de novo synthesis and not as a result of release from preformed 
stores. Furthermore, the amount of ET-1 released into the perfusate 
in response to hypoxia in the lung falls within the physiological 
concentration demonstrated to cause an increase in PPP and LW in 
this model.
Prepro ET-1 mRNA levels increase in whole lung homogenate 
following hypoxic perfusion, suggesting either an increase in the half 
life of prepro ET-1 mRNA or upregulation of ET-1 production.
Taken together, these results suggest that ETs and their receptors 
play an important role in the response seen to hypoxia in the rat lung.
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Future Work
Future studies of the involvement of endothelins in the effects of
hypoxia in the rat lung include:
a) Investigation into how hypoxia turns on endothelin synthesis, and 
how the decrease in PO2 is detected.
b) Investigation of the mechanism responsible for the increase in LW 
in response to hypoxia.
c) Measurement of ET release over time.
d) Determination of the cell type responsible for the ET release.
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Big ET-1 Big Endothelin-1
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P02 Partial pressure of oxygen
PPP Pulmonary perfusion pressure
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RT Reverse transcription
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